

Indexer: Dr Laurence Errington
E-mail: Laurence@errington-index.demon.co.uk

Abbreviations: AI (or FI), anal (faecal) incontinence; BOO, bladder outlet obstruction; EMG, electromyography; LUT, lower urinary tract; QoL, quality of life; SEP, somatosensory evoked potentials; UI, urinary incontinence.

(Typesetter. Please retain indexer's name at top of printed index, subject to publisher's approval.)

A

A- δ fibres/axons, 89, 90, 136-7

function, 90

inflammatory mediators and, 90

locations, 90

abdominal approach, *see* transabdominal approach

abdominal leak point pressure, 338

abnormalities, interpretation, 339

bladder volume and filling rate, 340

indications for measurement, 339-40

predictive value, 341

abdominal pressure, measurement, 323-4

absorbent products, 564-5, 665-72

costs, 668, 671, 973-4

disposable, 665-8

vs reusable, 670-1

FI and, 671, 1015

men, 564-5

older people, 665-72

reusable, 670-1

vs disposable, 670-1

accounting systems, 971

ACE (angiotensin-converting enzyme) inhibitors, 637

acetylcholine

detrusor contraction and, 35, 110, 111, 485

urethral contraction and, 57

acetylcholinesterase, 111

staining/detection, 100

acidosis, hyperchloraemic, 776

actin in bladder/detrusor smooth muscle, 24, 112-13

action potentials, detrusor, 27-9, 33-5

Addis Ababa Fistula Hospital, 914, 915

adenosine receptors and micturition, 119-20

ADH, *see* vasopressin

adherence, *see* compliance (patient)

adrenoceptor(s) (and adrenergic nerves/innervation), bladder

wall/detrusor, 33

aging and response to adrenergic stimulation, 134-5

α -adrenoceptor, 105

micturition and, 119

pudendal nerve reflex and, 99

α -adrenoceptor agonists/stimulants, 104, 110, 119

FI, 1010

stress incontinence, 104, 498

α -adrenoceptor antagonists, 104, 105, 119, 736

neurogenic UI, 736

older people, adverse urinary effects, 636

overactive bladder/sphincter, 104, 487, 494

children, 543

overflow incontinence, 500

β -adrenoceptor

β_3 -adrenoceptor, 495

agonists, 104

overactive bladder, 104, 487, 494-5

antagonists, stress incontinence, 498-9

advanced practice gerontological nurses, 957

aesthetics, absorbent pads, 668

aetiology (incl. risk factors), 205-12

AI/FI, 990, 998

children, 1020-1

older people, 1025-6, 1027-9

constipation, children, 1020-1

enuresis/wetting

day and day/night, 174, 535

night, 170-3

pelvic organ prolapse, 245-6

UI (in general), 941

men, *see* males

older people, 635-8, 678-84

in primary prevention, 941

research recommendations, 194

women, 182-7

urge incontinence, 109, 131

vesicovaginal fistula (non-obstetric), 849-50

afferent neurones/nerve supply, 24, 48, 65, 89-98

in aging, function, 134

ascending pathways in spinal cord, 117-20

endings, sensitivity, 93-8

inhibitors/blockers, 104

neurogenic UI, 729, 732-3

overactive bladder, 104, 496-7

in spinal cord injury, 137, 207

spinal projections, 91

see also sensory innervation

African women (and women of African origin)

epidemiology

of obstetric fistulas, 898, 900

of UI, 182

pregnant women, mortalities, 896

social consequences of obstetric fistulas, 912-14

age (and aging)

bladder, 133-5

cell phenotype in bladder wall, 215-16

physical properties, 134

bowel, 1026-7

detrusor overactivity and, 210, 629

in enuresis definition, 523

epidemiology of UI, 183

pelvic floor morphology, 70

stress incontinence surgical outcome and, 838

as UI risk factor, 683-4

in men, 189

in men, post-prostatectomy, 559

in women, 183

see also older people

Agency for Healthcare and Research and Quality (AHRQ; AHCPR), 940

aids, *see* anti-incontinence devices

airway obstruction, upper, children, 172-3

alarm, *see* enuresis alarm

alcohol injection, transvesical, 877

alcohol intake (and reduction)

men, 556

women, 576

allergy, latex, *see* latex allergy

allied health professionals, 950-1

alpha-adrenoceptors, *see* adrenoceptors

alternative (complementary) therapy, childhood FI, 1024

- ambulatory urodynamics, 320, 349-51
 - abnormalities, interpretation, 350
 - future study areas, 351
 - good urodynamic practice, 350
 - indications, 320, 350
 - predictive value, 351
 - study results, description, 349-50
 - technical aspects, 349
- amenorrhoea and vesicovaginal fistula, 907
- America/Americas, *see* Latin America; North America; USA
- American Foundation for Urologic Disease, 964
- amines, *see* catecholamines; monoamines *and specific amines*
- AMP, cyclic (cAMP), detrusor contraction and, 114
- AMS800 AUS, 812
- anal atresia (imperforate anus), 357, 1020
- anal canal
 - manometry, *see* manometry
 - sensation, *see* sensation
- anal incontinence, *see* faecal incontinence
- anal reflex, evaluation, 383, 414
- anal sphincter, 71-2, 998
 - age-related dysfunction/weakness, 1028
 - treatment, 1031
 - anatomy, 71-2
 - childbirth-related trauma, 1003-6
 - delivery technique and, 1008
 - physiology/pathophysiology, 996
 - pressure studies, *see* manometry
- anal sphincter, external (EAS), 71, 72
 - biofeedback enhancing reflex contraction of, 1010
 - dysfunction, 998
 - EMG, 395, 399, 400, 401, 403, 405, 999-1000
 - therapeutic application, 1010
 - latency of contraction, measurement, 738
 - motor evoked potentials, 410
 - repair, 1005-6, 1016-17, 1108
- anal sphincter, internal, 71
 - dysfunction, 998
- analgesia, epidural, labour, 219
- analytical epidemiology, 167
- anandamide, 96
- anatomy, LUT, 17-82
 - baseline, characterisation, in pelvic organ prolapse treatment trials, 256
 - MRI in standardisation of, 444-7
 - paediatric (congenital) abnormalities, *see* congenital/anatomic anomalies
 - see also specific parts*
- angiotensin-converting enzyme inhibitors, 637
- anoxia, urethral tension and, 110
- antegrade colonic lavage/enema (of Malone), 1019, 1024
- antibiotics
 - with artificial urinary sphincter, post-implantation, 812
 - diarrhoea associated with use of, 1029
 - with intermittent catheterisation
 - prophylactic, 712, 715
 - therapeutic, 715
- anticholinergics (antimuscarinics), 104, 486-90
 - bladder outlet obstruction (women), 845
 - bladder overactivity, 486-90
 - bladder training vs (women), 601
 - pelvic floor muscle training and, 603
 - costs/cost-effectiveness, 975, 978
 - enuresis
 - day and night-time, 543
 - night-time, 531
 - mixed smooth muscle relaxants and, 104
 - neurogenic bladder, 729, 730-2
 - children, 545
 - older people, adverse effects, 636, 637
- anticholinesterases, overflow incontinence, 500
- antidepressants, 104, 495
 - neurogenic UI, 732
 - nocturnal enuresis, 531
 - overactive bladder, 104, 487, 495
 - stress incontinence, 498-9
- antidiuretic hormone, *see* vasopressin
- anti-incontinence (incl. containment/collection/occluding) devices, 1071-2
 - costs, 973-4
 - men, 564-5, 674-5, 676
 - older people, 647, 665-77
 - trials, 1071-2
 - women, 604-14, 616-17, 675
 - literature search strategies, 618
 - research recommendations, 617
- antireflux surgery, children, 358
- anus
 - congenital conditions, 357, 1020
 - sensation, *see* sensation
 - surgical approach via, *see* transanal approach; transanorectal approach
 - see also entries under anal*
- apnoea, sleep, children, 172-3
- appendix, continent diversion using, 882
- appliances, *see* anti-incontinence devices
- Arab women, salt packed in vagina, 901
- arcus tendineus fascia pelvis, 68
- L-arginine/NO pathway, 64-5
- arousal (from sleep), children
 - infants, 515-16
 - nocturnal enuresis and, 172, 527-8
 - alarm facilitating arousal, *see* enuresis alarm
 - arousal training, 533
 - see also* waking
- arterial supply, bladder, 39
- artificial anal sphincter, 1017-18
- artificial bladder (prosthetic bladder), 883-5, 886
 - child, 768
 - development, 883-4
 - filling/voiding/continence with, 884-5
 - ideal, characteristics, 883
 - renal function with, protection, 884
- artificial urethral/urinary sphincter (=AUS), 769-70, 806-11, 879
 - children, 769-70, 774
 - component durability, 809
 - men, 806-11, 1092
 - complications and their treatment, 795, 806-12, 813
 - consensus protocol on follow-up, 812
 - diagnostic evaluation of UI after, 809-10
 - mechanical failure, 806, 812
 - older men, 664
 - post-prostatectomy UI, 234, 790-1, 792, 794
 - technique, 807-8
 - neuropathic patient, 879
 - women, 833, 835
- ascorbic acid (vitamin C) and connective tissue strength, 212-13
- Asia, maternal mortalities, 897
- Asia Pacific Continence Advisory Board, 960
- atherosclerosis and bladder fibrosis, 214
- ATP
 - receptors, afferent neurones, 93-4
 - in smooth muscle energetics, 107-8, 108-9
 - detrusor contraction, 111, 113, 483
 - supraspinal pathways in micturition and, 123
- atrial natriuretic hormone secretion, age-related changes, 629-30
- atrophic vaginitis, 636
- atrophy, urethral, with artificial urinary sphincter, 806, 811-12

- atropine (hyoscyamine)
 - in bladder overactivity, 486, 487
 - doxazosin and, 494
 - resistance to, 483, 483-4
- attention deficit hyperactivity disorder, 173
- Australia
 - AI/FI in
 - older people, 1026
 - prevalence, 989
 - Continence Foundation of, 963
 - costs in (of UI), 973
 - cost-effectiveness analysis, 977-8
 - of routine care, 974
 - family doctors in, 955
 - health surveys with information on UI, 971
 - medical professionals, education/training, 946, 948, 948-9, 949
 - pharmacists, 951
 - public awareness campaign/materials, 943, 943-4
- auto-augmentation (bladder myectomy)
 - child, 767
 - men, 799
 - neuropathic patient, 874-5
 - women, 849
- autoimmunity, neuroprotective, 98
- autologous grafts
 - for suburethral sling, 831
 - urothelium, *see* urothelium
- automatic bladder, *see* reflex bladder
- autonomic ganglia and ganglion cells, 50, 99-103
 - electrophysiological studies, 101
- autonomic nervous system, 99-103
 - bladder, 46-8
 - histochemistry, 100
 - location/organisation, 99-100
 - tests, 416
 - see also* parasympathetic nervous system; sympathetic nervous system
- autonomic neuropathy
 - open bladder neck in, 454
 - tests, 416
- autosuggestion, nocturnal enuresis, 532
- axon collaterals, 90-1
- axon reflexes, 90-1

B

- baclofen
 - micturition effects, 120
 - overactive bladder, 496
- bacteriology, older people, 642, 645
- bacteriuria
 - condom catheters and, 727
 - intermittent catheterisation and, 712-13
 - older people, 642, 645
- balloon (of indwelling catheters), 718, 720
- balloon systems
 - in biofeedback for FI, 1011
 - pressure measurement
 - abdominal, 323
 - intravesical, 323
 - urethral, 335, 337
- basal ganglia lesions, 125-6
- bead-chain cystourethrography, 435
- bedding, skin care, pads and, 565
- bedpads (bedding underpads), 565, 668-9
 - disposable, 668-9
 - reusable, 670
- bedside cystometry, older people, 642, 645, 646
- behaviour, health-seeking, triggers for, 944-5
- behavioural disturbances
 - FI and, 1021
 - nocturnal enuresis and, 172

- behavioural therapies, 1071
 - men, 563
 - neurogenic UI, 703-8
 - nocturnal enuresis (children), 531-5
 - older people, 647-59
 - trials/research, 1071, 1113
 - women, pelvic floor muscle training vs, 583
 - see also* physical therapies
- Belgium, continence awareness campaign, 943
- benign prostatic hyperplasia - BPH (and benign prostatic disease in general)
 - hypertension and, 139
 - lidocaine for overactive bladder in, 141
 - prostatectomy for, *see* prostatectomy
 - questionnaires (validated), 305
- beta-adrenoceptors, *see* adrenoceptors
- beta error, 1051
- bethanochol chloride, 736
- BFLUTS, *see* Bristol female LUTS questionnaire
- bias in trials, 1053-4
- bilharziasis, *see* schistosomiasis
- bimanual examination, pelvic organs, 379-80
- biochemical tests, 465-6
- biofeedback
 - day/night-time enuresis, 541-2
 - FI, 1010-12, 1108
 - children, 1024
 - modalities, 1010-11
 - older people, 647-8, 647-50
 - post-prostatectomy UI, 560
 - vaginal, pelvic floor muscle training vs (women), 584-6
- biothesiometry, penile, 411
- bisacodyl suppositories, 1013
- black women, epidemiology of UI, 182
- bladder
 - activity
 - excessive, *see* bladder overactivity
 - repetitive electrical stimulation effects on, 98
 - afferent neurones
 - properties, 89-90
 - in spinal cord injury, 137, 207
 - agenesis, 757-9
 - in aging, *see* older people
 - anatomy, 20-4, 24-50
 - external, 20
 - in female (and relations to other structures), 20-2
 - internal, 20
 - in male, *see* male
 - artificial, child, 768
 - automatic/reflex, *see* reflex bladder
 - bilharzia scarring, *see* schistosomiasis
 - capacity, *see* bladder capacity
 - compliance, *see* compliance
 - connective tissue, *see* connective tissue
 - control, disorders, pathogenesis, 483
 - damage in stress incontinence surgery, 836
 - denervating agents injected into (subtrigonal), 877
 - women, 847
 - development, 515-16
 - distended (overdistended), leakage from (=overflow incontinence),
 - drug therapy, 499-500
 - distension (technique), *see* cystodistension
 - duplication, 757-9
 - dysfunction, *see* bladder dysfunction
 - electrical stimulation, *see* electrical stimulation
 - emptying, facilitation
 - with bladder expression, 706
 - with catheters, *see* catheters
 - with drugs, 729, 736

- emptying, impairment/failure
 - children, postoperative, 774-5
 - men, 1092
 - older people, 638
 - surgery, 867-73
 - women, devices treating, 605
 - see also* overflow UI; urine retention
- endoscopy, female, 458-9
- fibrosis, 213-15
 - causes, 214
 - children, 214-15
- filling
 - afferents responding to, 90
 - blood flow and effects of, 39-43
 - pressure--volume studies during, *see* cystometry
 - prosthetic bladder, 884-5
 - rate, in leak point pressure measurement, 340
 - ultrasound assessment, 438
- fistulas between vagina and, *see* vesicovaginal fistulas
- functional alterations, *see* bladder dysfunction
- inflammation, *see* cystitis
- injury, *see* injury
- irrigation with indwelling catheters, 722-3
- ischaemia, *see* ischaemia
- lazy (syndrome), 539, 542
- myectomy, *see* autoaugmentation
- neurogenic, *see* neurogenic bladder
- orthotopic replacement, *see* neobladder
- overactive, *see* bladder overactivity
- pharmacology of peripheral pathways to, 103-6, 482-3
- pressure within, *see* intravesical pressure
- reconstructive surgery, *see* cystoplasty
- rectal, augmented, 763, 764
- role/functional properties, 107
- sensation
 - children (with enuresis), 522
 - in cystometry, 329, 410-11, 522
 - gene knockout studies, 144, 145
- storage phase, switch to voiding phase, 86
- stroma, 35-9
 - role, 39
- support/suspension, 432-3
 - anterior suspension defects, 433
 - base insufficiency, 433
 - imaging, 432-3
 - posterior suspension defects, 433
- surgery circumventing, *see* urinary diversion
- training, *see* bladder training
- transection, neuropathic patient, 877
- transmembrane transport, 46
- trigone of
 - denervating agents injected through/below, *see* denervating agents (*subheading above*)
 - innervation, 1014
- unstable, *see* bladder instability
- urine leakage, *see* leakage
- urine reflux into ureter, *see* vesicoureteric reflux
- volume
 - bladder pressure and relationship to, measurement, *see* cystometry
 - in leak point pressure measurement, 340
 - pad test and, 461
 - urethral pressure varying with, 335
- see also* entries under cyst-
- bladder cancer
 - enterocystoplasty and, 778-9
 - indwelling catheters and, 722
 - neobladder for, 795
- bladder capacity
 - children, 516-17
 - maximum cystometric, 522
 - post-prostatectomy, 558
 - reduced, as surgical indication, 762
 - males, decreased, 562-3, 800-1
 - drug therapy, 562-3
 - surgery, 800-1, 813
 - older people, 134
 - cystometric, 643, 645
- bladder chart, *see* frequency/volume chart
- bladder "cycling", 846-7
- bladder diary, *see* frequency/volume diary
- bladder dysfunction (and functional changes), 206-12, 233-4
 - with artificial urinary sphincter, 806
 - treatment, 811
- children, 536-7
 - nocturnal, 172
- older people, 629-95
 - pelvic organ prolapse comorbid with, 247-8, 835-6
 - post-prostatectomy, 233-4, 353
 - rehabilitation, 540-1
- bladder expression, 702, 705-8
- bladder exstrophy, 357, 757, 797-9
 - persisting incontinence, management (later life), 797-9, 813
- bladder flaps for urethral reconstruction
 - non-obstetric fistulas, 853
 - obstetric fistulas, 925
- bladder instability (unstable bladder)
 - contractions, metabolic studies, 131-2
 - endoscopy, 459
 - innervation in, 30
 - nocturnal, children, 527
 - signals generated, 216-17
 - smooth muscle changes, 127
- bladder neck (urethrovaginal junction; bladder outlet)
 - anatomy, 50-2
 - endoscopic evaluation
 - female, 458
 - male, 459-60
 - innervation, 101
 - mobility (and hypermobility)
 - assessment, 385, 445
 - recommended management in women concerning, 1096
 - needle suspension, *see* needle suspension
 - obstruction, *see* bladder outlet obstruction
 - open, causes and imaging, 453-4
 - resistance, surgery decreasing, 872-3, 886
 - stimulation, sacral reflexes obtained, 414
 - support devices/prosthesis, intravaginal, 607-10, 616
 - surgery (incl. reconstruction)
 - children, 769-79
 - revision with exstrophy/epispadias, 798
 - transurethral incision of (TUIBN), women, 845
 - ultrasound, 436, 438, 441
 - underactivity in women, devices, 605-14
 - see also* detrusor--sphincter dyssynergia
- bladder obstruction
 - children, 522-3
 - day or day/night wetting and, 174
 - ischaemia and, 132-3
 - NGF and, 130, 135
 - NOS and, 144
 - at outlet, *see* bladder outlet obstruction
 - urodynamic studies in men, 353
- bladder outlet, *see* bladder neck; bladder outlet obstruction
- bladder outlet obstruction (outflow obstruction; BOO), 135, 207-10
 - animal models, 215
 - brachytherapy-induced (in prostate cancer), 233, 794
 - cell phenotype in bladder wall in, 215-16
 - children with ureterocele, 357-8
 - detrusor overactivity with, 207-10

- bladder outlet obstruction (outflow obstruction;BOO) 1-cont'd
 - men, 230-4, 1064
 - nocturnal enuresis, 557
 - outcomes research, 1064
 - pharmacotherapy, 562
 - recommended management, 1092
 - metabolic studies, 131-2
 - spinal micturition reflex in, 135
 - women, 841-5
 - diagnosis, 842-3
 - management, 844-5, 1096
 - postoperative, 841-5
- bladder overactivity (overactive bladder – OAB, unstable bladder, bladder instabilities, detrusor overactivity and overactive syndrome),
 - 85, 126-45, 206-12, 486-97
 - central models, 135-45, 207
 - children, 538
 - idiopathic, 540
 - nocturnal, 527
 - costs of treatment, 972, 976
 - drugs therapy, 104, 486-97
 - older people, 659-60
 - electrical neuromodulation, 737, 739, 799
 - epidemiology, 167
 - peripheral models, 126-35
 - QoL assessment, 284
 - uninhibited, 331
 - see also* detrusor overactivity
- bladder reflex, *see* micturition reflex
- bladder rehabilitation, 540-1
- bladder relaxants (incl. smooth muscle relaxants), 729-32
 - mixed anticholinergic and, 104
 - in neurogenic UI, 728-9, 729-32
 - intermittent catheterisation and, 711
 - see also specific (classes of) drugs*
- bladder retraining, *see* bladder training
- bladder–sphincter dysfunction, *see* bladder dysfunction; urethral sphincter dysfunction
- bladder training/retraining/discipline/drill/re-education
 - children, 540
 - men, 563
 - women, 598-604, 616
 - adverse effects, 604
 - combined with other treatments, 602-4
 - factors affecting outcome, 604
 - literature search strategies, 618
 - no treatment vs, 600-1
 - other treatments vs, 601, 602-3
 - research recommendations, 617
- bladder wall
 - anatomy, 24-50
 - nerves/neurones in
 - in detrusor overactivity, 129
 - immunostaining, 100-1
 - structural changes, 213
 - thickness, imaging, 454
- bleeding/haemorrhage
 - with intermittent catheterisation, from urethra, 713
 - stress incontinence surgery, 836
- blinding in trials, 1048
- block randomisation, 1052
- blood flow
 - bladder, 39-43
 - importance, 43
 - mucosa, 109
 - urethral, 63
- blood vessels, bladder, 39-43
 - role, 43
 - structure and properties, 39-43
- Blueprint for Continence Care, 958
- BNDF (brain-derived neurotrophic factor), 97, 98
- Bonferroni correction, 1057
- bothersomeness, measures, 281
 - recommended questionnaires, 306
- Botox® , *see* botulinum toxin A
- botulinum toxin A (BotoxR[O] and DysportR[O] 900IE), 735-6, 873, 877-9
 - in detrusor overactivity, 735-6, 877-9
 - intermittent catheterisation and, 711
 - outlet resistance reduction with, 873
- bowel (intestine)
 - ageing, 1026-7
 - in alternative continence channel construction, 773
 - neuropathic patients, 882
 - bladder reconstruction/augmentation using (=enterocystoplasty)
 - children, 763-7, 799-800
 - complications, 775-9
 - men, 799-800, 811
 - neuropathic patients, 874
 - with seromuscular patch, 767-8
 - for unsuccessful exstrophy-epispadia surgery, 798
 - women, 848-9
 - see also* neobladder
 - irritable (syndrome), postpartum, 1009
 - neuropathic patients
 - bladder surgery using, 874
 - and causes of constipation and FI, 1020
 - defaecation and, 997
 - management, 1013-14
 - see also specific regions*
- bowel habit/function
 - assessment, 1082
 - child, 1019
 - dysfunction, management, 1088
 - intestinal segment removal affecting, 777
 - see also* constipation
- bowel symptom questionnaire, 993-4
- bowel training, neurological patient, 1013-14
- bowel washout regimes, 1014
- boys
 - bladder capacity, 516
 - nocturnal enuresis prevalence, 525
 - see also* children
- brachytherapy, prostate cancer, 794
 - outflow obstruction after, 233, 794
- brain, 456-7
 - detrusor overactivity related to, 207
 - imaging, 456-7, 467, 468, 1084
 - micturition studies, 124-5, 457, 482
 - magnetic stimulation, 409
- brain-derived neurotrophic factor, 97, 98
- brain mapping, evoked potential, 413
- brainstem in micturition, 121-2
 - pharmacology, 122-3
- Brazil, continence services, 957
- Brief Male Sexual Function Inventory for Urology, 286
- briefs, *see* diapers
- Brindley Device, 869, 870, 871
- Bristol female LUTS (BFLUTS) questionnaire, 278, 284
 - BFLUTSsex questionnaire, 287
- Britain, *see* UK
- bulbocavernosus graft/flap, obstetric fistulas, 917, 921
- bulbocavernosus muscle, EMG, 395, 401
- bulbocavernosus reflex evaluation, 383, 414-15, 415
 - technical standards recommendations, 418
- bulbourethral sling, 812, 813
- bulking agents, periurethral injection
 - children, 769
 - men
 - older, 664
 - post-prostatectomy, 791, 792-3, 794
 - neuropathic patients, 880
 - women, 833, 845
 - BOO following, 841-2
 - older, 663

Burch colposuspension, 827
haemorrhage, 836
butoxamine, 494

C

C-fibres/axons, 89, 90, 483
detrusor overactivity and, 211
function/activity, 90, 95, 483
inflammatory mediators and, 90
locations, 90
in spinal cord injury/lesions, 137, 207

C3 clamp, 565

caffeine intake (and reduction)

FI and, 1015
men, 556
older people, 683
women, 576, 615

Cajal's interstitial cells, *see* interstitial cells

calcitonin-gene related peptide (CGRP), 48, 50, 91
distribution (and its detection), 101, 102

calcium ion (and Ca^{2+} channels)

antagonists
in bladder overactivity, 490
older people, adverse urinary effects, 636-7
detrusor and
contraction of, 29, 33-5, 110-11, 113-14
ischaemic neuronal damage and, 133
relaxation of, 111-12
urethral tension and, 110

calculi, *see* stones

Canada

continence organisation, 963
health surveys with information on UI, 971
nurses, 956
nurse continence advisers, 948
specialist, 949

cancer, *see* bladder cancer; prostate cancer

cannabinoids, endogenous, 96

capillaries, bladder, 39, 43

capsaicin, 496-7, 732-4

primary afferent neurones sensitive to, 65, 496-7
receptors (vanilloid receptors type 1; VR1), 91-3, 96
therapeutic use, 496-7, 732-3

Capsure, 612

cardinal ligaments, 67

damage, 223

care, *see* continence care; routine care

Caribbean, maternal mortality, 897

case-control studies, 167

catecholamines, detrusor responses to, 33

catheters, 672-4, 708-25

as anti-incontinence devices, self-retaining, 605-6
condom, *see* condom
fistulas in women
non-obstetric, 850
obstetric, after repair, 917
indwelling, *see* suprapubic catheter; urethral catheter
intermittent, *see* intermittent catheterisation
neurogenic UI, 708-25
older people, 672-4
self-catheterisation, *see* self-catheterisation
urethral, *see* urethral catheters
in urodynamic studies, 322, 340
in ambulatory studies, 349
valves, 673-4

cauda equina lesions/injury, 700-1, 702-3

bladder behaviour with, 703
EMG, 404, 405

cauda equina stimulation, *see* sacral nerve roots, anterior, electrical stimulation

cause, *see* aetiology

caustic substances in vagina, fistulas caused by, 901

cecum in bladder reconstruction

child, 765
intestinal complications, 776
see also ileocaecal valve

cell(s)

bladder wall, phenotype changes in aging or outlet obstruction, 215-16
in wound repair, 216

cell biology, lower urinary tract, 17-82

central nervous system (and central pathways), 115-26

imaging, 456-7, 467, 468, 1084
LUT function and role of, 86, 115-26
human studies of micturition, 124-6
pharmacological aspects, 118-20, 122-3, 481-2
serotonin and, 105
neuropathic UI and lesions of, 699-703, 1100, 1102
overactive bladder and, 135-45, 207
serotonin action, 105
see also brain; spinal cord

cerebral palsy

day or day/night enuresis, 174
urodynamic studies in men, 357

cerebral SEPs, 412, 413-14

cerebrovascular accident (CVA incl. stroke), 126, 682-3

AI, 1028
bowel training, 1014
detrusor/bladder overactivity and, 126, 142, 699
neuroimaging, 467

cervical damage in obstructed labour, 907-8

CGRP (calcitonin-gene related peptide), 48, 50, 91

change, responsiveness to, *see* responsiveness to change

Changes in Urinary Function (questionnaire), 283

chemical tests, 465-6

childbirth (parturition by vaginal delivery), 218-22, 223-4, 1002-8

FI after, 221-2, 1002-8
physical therapies in prevention, 597
instrumental delivery, effects, 1008
obstructed labour and injury in, 902-14
open bladder neck, imaging, 454
pelvic floor and effects of, 217, 218-22, 223-4
imaging, 224, 445
morphology of, 70
pathophysiologic mechanisms of injury, 218-19
prolapse, 223-4, 245
pelvic floor muscle exercises after, 220
perineal trauma, 220-1, 1005-7
physical therapies after, preventive effects, 596-7, 597
pudendal nerve conduction tests after, 219, 407-9
QoL questionnaire on UI, 288-9
as risk factor for UI, 183-4
in subsequent pregnancy after 3rd/4th degree obstetric tear, management, 1007
Traditional Birth Attendants (Ethiopia), 957
see also labour

children, 169-75, 513-51, 755-83, 1068-9, 1086-9

assessment/evaluation, 518-23, 1086, 1088
history-taking, *see* history-taking
physical examination, *see* physical examination
bladder fibrosis, 214-15
classification of UI, 526
congenital/anatomic anomalies, *see* congenital/anatomic anomalies
constipation, *see* constipation
enuresis, *see* enuresis

- faecal incontinence, 1019-23
 - assessment/investigations, 358, 1021-2
 - associated disability, 1024
 - causes, 1020-1
 - definitions, 1019-20
 - management, 1022-4
 - outcome, 1024
 - secondary effects, 1021
- imaging, 761-2
- management of UI, 513-51, 755-83, 1086-9
 - conservative, 513-51
 - recommendations, 1086-9
 - surgical, *see* surgery
- neuroimaging, 456
- nocturnal polyuria, 172
- outcome assessment/research, 1068-9
 - FI, 1024
- research recommendations, 1112
- unresolved problems (in later life), management, 797-9
- urodynamics, *see* urodynamic studies
- see also* boys; girls; infants
- choline acetyltransferase distribution (and its detection), 100
- cholinergic drugs, neurogenic UI, 736
- cholinergic nerves/innervation
 - bladder neck, females, 50
 - bladder wall/detrusor, 30, 33
 - see also* anticholinergics; muscarinic receptors
- cholinesterase inhibitors, overflow incontinence, 500
- chondroitin sulphate proteoglycan, 38-9
- chronic pelvic pain syndrome, men, 564
- cigarette smoking, *see* smoking
- circumcision, female, 901-2
- clam cystoplasty, intestinal complications, 776
- clam-type devices, 607, 608
- clamps, penile, 565, 676
- clenbuterol
 - overactive bladder, 494-5
 - stress incontinence, 499
- clinical trials, *see* trials
- clitoris, *see* circumcision, female; dorsal clitoral nerve
- cloacal exstrophy, 757
- clomipramine model of depression, 142-3
- cluster sampling, 1051
- coccygeus fixation, 252, 258
 - see also* parasacrococcygeal incision
- codeine phosphate, 1009
- cognitive (intellectual) impairment
 - constipation and FI with, 1028
 - treatment, 1031
 - oxybutinin-induced, 492
 - tests for, older people, 643
 - UI risk with (especially elderly), 643, 678-92
 - men, 190
 - preventive strategies, 678-9
 - women, 187
- cognitive restructuring, nocturnal enuresis, 532
- cohort studies, 167
 - nocturnal enuresis, 170
- cold sensation tests, *see* temperature sensation tests
- collagen, 35-8, 466
 - analysis, 466
 - bladder wall, 35-8, 212, 216
 - fibrosis in children and, 217
 - types, 38
 - pelvic floor dysfunction and, 69
 - pelvic organ prolapse and abnormalities of, 246
- collagen injections, periurethral (as bulking agent)
 - children, 769
 - men
 - older, 664
- collagen injections, periurethral (as bulking agent) – cont'd
 - post-prostatectomy, 791, 792-3, 794
 - neuropathic patients, 880
 - women, 833
 - BOO following, 841-2
 - older, 663
- collection devices, 674-6
 - men, 565
 - older people, 674-6
 - women, 606-7, 675
- colon
 - antegrade lavage/enema (Malone's), 1019, 1024
 - cystoplasty
 - carcinogenicity, 778
 - child, 765-6
 - metabolic complications, 776
 - see also* sigmoid colon
- colorectal surgery, AI following, 990-1, 992
- colostomy, 1019
 - rectourethral fistula, 803
- colpocystourethrography, voiding, 435
- colporrhaphy, 826
 - anterior, 253-4, 260, 826, 835
 - complications, 836
 - posterior, 261
- colposuspension, 662-3, 827
 - apical suspension, 252-3, 258
 - complications, 836
 - laparoscopic, 828, 829, 835
 - Moschovitz operation with, 836
 - older people, 662-3
 - outcome of
 - detrusor instability and, 840
 - functional and anatomic, evaluation, 376
 - previous history of continence surgery influencing, 839
- commissure, dorsal (DCM), 116, 117
- community continence service models, 955-6
- complementary therapy, childhood FI, 1024
- compliance (bladder/detrusor)
 - child, 522
 - low, drug therapy, 728-9
 - males, post-prostatectomy, 558
- compliance (patient with treatment) and non-compliance, 945
 - children, 1069
 - costs and, 975
- compliance (rectal), *see* rectum
- complications
 - of procedures, *see* safety aspects
 - of UI, costs related to, 976-7
- computerised tomography (CT)
 - CNS, 456-7, 1084
 - lower urinary tract, comparisons with other imaging methods, 449-50
 - upper urinary tract, 430
- concealment of allocation, 1053
- concentric needle electromyography (CNEMG), 396-402
 - technical standards recommendations, 418
 - urinary retention in women, 406-7
- condoms (penile sheaths; condom catheters), 565, 674-5, 725-8
 - applications, 726
 - comparing different types, 728
 - results, 726-8
- conduction, *see* nerves
- conduit (non-continent) urinary diversion
 - conversion to continent diversion, 883
 - neuropathic patients, 882-3
- confidence intervals, 1054
- confusional state, older people, 636
- congenital/anatomic anomalies, 357-8, 526, 757, 757-9, 759, 760
 - anorectum, 357, 1020
 - fistula
 - rectourethral, 802
 - urethrocuteaneous, 802
 - unresolved problems from, management, 797-9

- connective tissue, 212-17, 466-7
 - analysis, 466-7
 - bladder, 38, 212-17
 - in pelvic floor, 69
 - paraurethral, 63-4
 - urethral support by, 68
 - strength, 212-13
- consent, informed (in trials), 1053
- conservative management, 479-624, 1071-3
 - children, 513-51
 - FI, 1009-15
 - absorbent products and, 671, 1015
 - adults, 1009-15
 - men, *see* males
 - neuropathic UI, 697-754
 - older people, *see* older people
 - trials, *see* trials
 - women, *see* females
 - see also specific methods*
- consistency, internal, questionnaires, 271
 - ICIQ, 300
- Consolidated Standards of Reporting Trials, *see* CONSORT
- CONSORT statement/guideline, 1058, 1072, 1074, 1111, 1112, 1113
 - flow diagram, 1056, 1057
- constipation
 - children, 1020-1
 - causes, 1020-1
 - with enuresis, 173, 519-20, 538
 - management, 1022, 1024
 - quantification, 519-20
 - neurological patients, 1013
 - older people, 1027-8
 - women, 577, 615
 - pelvic organ prolapse and, 245-6
 - see also* faeces, impaction
- construct validity of questionnaires, 271
 - ICIQ, 300
- containment devices, 564-5
 - older people, 665-77
- content/face validity of questionnaires, 270-1
 - ICIQ, 299-300
- continence awareness, promotion, 940-5, 1110
- continence care, 937-64
 - education, *see* education
 - organisations involved, 952-60, 1110
- continence nurse advisers, 948
- continence nurse practitioners (CNP), 949, 956
- Continence Promotion Committee, *see* ICS
- continent urinary diversion
 - child, 765-7
 - psychological consequences, 779
 - conduit (non-continent) diversion converted to, 883
 - neuropathic patients, 882
 - for unsuccessful exstrophy-epispadia surgery, 798
- CONTInet, 951, 959, 959-60
- contraction, 110-15
 - anal sphincter, latency measurement, 738
 - detrusor (bladder) smooth muscle, 24-35, 110-15, 483-6
 - in ambulatory urodynamics, 350
 - in vitro studies of, 27
 - machinery, 24-7, 112-15
 - neuronal control, 30
 - surgery decreasing contractility, 873-8, 886
 - surgery increasing contractility, 863-4, 885
 - pacemaker signals to, 103
 - pelvic floor muscle, voluntary, *see* pelvic floor muscle training
 - rectal wall contractility, 997
 - unstable bladder, metabolic studies, 131-2
 - urethral smooth muscle, 57-60
 - neuronal control, 57-60, 483-6
 - urethral sphincter, *see* urethral sphincter
 - see also* excitation--contraction coupling
- controlled studies and trials (incl. randomised trials/RCTs), 1049, 1050, 1111
 - pelvic organ prolapse surgery, 256
 - placebos, *see* placebos
 - questionnaires in, 290-1
 - reporting, 1058
- conus (medullaris)
 - electrical stimulation, 867
 - lesions (=lower motor neurone), 702
 - bladder expression, 705
 - EMG, 405
- Conveen device, 608, 609
- Conveen "tampon", 608
- corrosive (caustic) substances in vagina, fistulas caused by, 901
- cortical pathways in micturition, 123-6
- cost(s) (and economic/financial issues), 965-83, 1063
 - absorbent products, 668, 671, 973-4
 - continence services, 957-8
 - estimating costs, 1063
 - information provided by estimates, 968
 - methods, 969-70
 - reasons for, 967-8
 - future research priorities, 980-1
 - see also* funding
- cost-benefit analysis, 968-9, 979-80
- cost-effectiveness, 968, 977-8, 1063
 - bladder expression, 707
 - condom catheters, 727
 - continence services, 958
 - electrical neuromodulation, 738
 - electrical stimulation of pelvic floor, 740
 - intermittent catheterisation, 716-17
 - triggered reflex voiding, 704
- cost-minimisation analysis, 1063
- cost-utility analysis, 968, 978-9, 1063
- cotton swab test, 384-5, 385
- coughing
 - detrusor overactivity provoked by, cystometry, 329, 330
 - leak point pressure during, 338
 - ultrasound measurements, 438
 - urethral pressure profile during, 335
- creatine kinase and creatine phosphate, 108-9
- Credé manoeuvre, 705-8
- criterion validity, questionnaires, 271
- cromakalim, 490
- crossbridges, actin--myosin, 24, 112-13
- cross-infection risk, leg bags, 676
- crossover effects (in crossover trials), 1049
- crossover trials, 1049
- cryosurgery, prostate, 794-5
- culdeplasty, McCall, 252, 258
- cultural aspects, prompted voiding, 657
 - see also* religion
- Cunningham clamp, 565, 676
- cutaneous care/problems etc., *see* skin
- cyclic nucleotides, *see* AMP; GMP
- cyclo--oxygenase inhibitors, *see* prostaglandin synthesis inhibitors
- cystitis (bladder inflammation), 135
 - bilharzial, *see* schistosomiasis
 - NGF and, 135
 - NO and, 46
 - radiation-related, enterocystoplasty, 801
 - tuberculous, enterocystoplasty, 801
- cystocele, 68
 - MRI, 448
- cystocoloproctography (or cystoproctography), pelvic organ (incl. prolapse), 249, 449-50
- cystodistension in detrusor instability
 - neuropathic patient, 875
 - women, 846-7

- cystolysis
 - neuropathic patient, 875
 - women, 848
- cystometric biofeedback, day/night-time enuresis, 541-2
- cystometric capacity
 - maximum, child, 522
 - older people, 643
- cystometry (filling cystometry), 320, 328-33
 - abnormalities, interpretation, 330-1
 - artificial urinary sphincter failure, 809
 - bedside, older people, 642, 645, 646
 - childhood enuresis, 522
 - future study areas, 333
 - good urodynamic practice, 332
 - indications, 320, 331-2
 - predictive value, 332-3
 - safety, 330
 - sensory measurements during, 329, 410-11, 522
 - study results, description, 330
 - technical aspects, 328-9
- cystoplasty (bladder reconstruction/augmentation - reservoirs, pouches etc.),
 - children, 763-9
 - men, 800-1
 - psychological consequences, 779
 - see also* neobladder
- cystoproctography/cystocoloproctography, pelvic organ (incl. prolapse), 249, 449-50
- cystoscopy, *see* endoscopy
- cystourethrography, voiding (VCUG), 431-5, 1084
 - child, 762
 - with enuresis, 521
 - female, 431-5, 467
 - with BOO, 844
 - see also* urethrography
 - men
 - artificial urinary sphincter failure, 811
 - preoperative, 788
 - other imaging (VCUG) methods compared, 435, 438
- cystourethroscopy, *see* endoscopy

D

- DAN-PSS-1, 278
- Danish LUTS (questionnaire), 279
- darifenacin, 489-90
- data
 - collection
 - cost studies, 970
 - differing methods, 192
 - in trials, 1048, 1059
 - interpretation/analysis, 1048, 1056
 - cost studies, 970-1
 - minimum data set, *see* minimum data set
 - quality
 - ageing lower bowel, 1026-7
 - FI in older people, 1027-8, 1030, 1030-1
 - international continence organisations, 958
 - pad test, 460-4
 - professional education, 945-51
 - promotion of continence awareness, 940
 - service/care delivery, 952
 - urodynamic, variability, 325
- databases, QoL/symptom information, 269
- daytime and night-time wetting (co-existent), 169, 173-5
 - causes/risk factors, 174, 535
 - classification, 537-40
 - diagnosis, 535
 - long-term outcome, 174-5
 - prevalence, 173-4, 536
 - treatment, 540-3

- daytime dryness, epidemiology, 174-5
- daytime frequency and paediatric bladder instability, 527
- daytime wetting (diurnal enuresis), 173-5, 1086
 - causes, 169
 - definitions, 169
 - long-term outcome, 174-5
 - night-time and, *see* daytime and night-time wetting
 - prevalence, 173-4
 - risk factors, 174
 - urodynamic studies, 358
- DDAVP, *see* desmopressin
- deaths, maternal, obstetric fistulas and, 896-8
- decision-making, joint, 1085
- deep tendon reflexes, evaluation, 383-4
- defaecating proctography, *see* defaecography
- defaecation, 997
 - difficulties (dyschezia), older people, 1027, 1028
 - mechanism, 997
- defaecography (defaecating/evacuation proctography), 1001
 - in pelvic organ prolapse, 248, 249, 249-50
- definitions and terminology, 1080
 - enuresis, 169, 326, 523, 1080
 - in epidemiological studies, 168-9
 - differing, 191-2
 - frailty, 627
 - incontinence, *see* incontinence
- delirium, older people, 636
- delta opioid receptor agonists, 99, 117
- dementia
 - constipation and FI associated with, 1028
 - treatment, 1031
 - UI risk, 678-82
 - preventive strategies, 678-82
 - women, 187
- demographics in outcome research, 1059
- denervation (pathological), *see* nerve injury
- denervation (technique), 875-7
 - in detrusor instability/overactivity
 - neuropathic patient, 875-7
 - women, 847-8
- Denmark
 - health surveys with information on UI, 971
 - questionnaires assessing symptoms of UI, 278, 279
- Department of Health (UK), nursing services, 948, 954
- depression, 976
 - overactive bladder and, 142-3
 - urge incontinence and, 976
 - gender and, 143-4
- Der Inkontinenz-Fragebogen, 279
- dermatitis, "diaper", 667
- dermatology, *see* skin
- descriptive epidemiology, 167
- desmopressin (DDAVP)
 - bladder overactivity, 487, 496
 - nocturia
 - men, 563
 - older people, 633-5
 - nocturnal enuresis, 496, 530
 - and alarm, 530-1
 - non-responders, 531
- detrusor
 - areflexia
 - and areflexia of sphincter, 702
 - and hyperreflexia of sphincter, 702
 - compliance, *see* compliance
 - contraction, *see* contraction
 - dysfunction (in general), children, 537
 - hyperreflexia, *see* neurogenic detrusor overactivity

- detrusor – cont'd
 - instability, *see* detrusor overactivity
 - mechanics, 27
 - myectomy, *see* auto-augmentation
 - nerves running in, staining/labelling, 100
 - NO and, 33, 64
 - preoperative functional assessment, men, 789
 - purinoceptors, 106
 - relaxation, 111-12
 - urethral sphincter contraction and, *see* urethral sphincter, contraction
 - underactivity
 - men, management, 1092
 - women, treatment, 605-6, 1096
 - see also* smooth muscle, bladder wall
- detrusor leak point pressure, 338
 - abnormalities, interpretation, 338-9
 - bladder volume and filling rate, 340
 - definition, 338
 - indications for measurement, 339-40
 - predictive value, 341
 - transurethral catheters and, 340
- detrusor overactivity (instability), 127-33, 207-12, 799-800, 813
 - with artificial urinary sphincter, 806
 - treatment, 811
 - common features, 127
 - cystometry, 329, 331
 - definition of, 327, 1080
 - definition of outcome in women, 1066
 - drug therapy, 592
 - electrical stimulation, men, 799
 - electrical stimulation, women, 590, 591-2
 - and/or pelvic floor muscle training, 591
 - medication vs, 592
 - endoscopy, 458-9
 - idiopathic, 106, 211-12, 1080
 - men, management, 799-800, 1092
 - women, recommended management, 1096
 - incontinence due to
 - definition of, 327
 - patient history in prediction of urodynamic findings, 328
 - neurogenic, *see* neurogenic detrusor overactivity
 - non-neurogenic, *see* non-neurogenic detrusor dysfunction
 - older people, 210, 629
 - phasic, 331
 - post-prostatectomy, 558
 - smooth muscle of bladder wall in, 127-9
 - stress incontinence surgery outcome and, 840
 - surgery
 - men, 799-800, 1092
 - women, 846-7
 - see also* bladder overactivity
- detrusor pressure measurement, 324
 - in ambulatory studies, 350
- detrusor--sphincter dyssynergia
 - botulinum toxin (intravesical injection), 873
 - children, drug therapy, 545
 - consequence, 702
 - transurethral external sphincterotomy, 872-3
 - urodynamic studies, 355
- detrusorectomy, results/complications, 775
- developing world
 - obstetric fistula, *see* fistula
 - services in, 957
- development, bladder/sphincter control, 515-16, 535
- devices, *see* anti-incontinence devices
- diabetes insipidus, children, 173
- diabetes mellitus, 701
 - adult, 557
 - AI and, 1028
 - children, 173
- diagnostic tests, 1081-4
 - costs, 969
 - highly recommended, 1081-2
 - non-recommended, 1084
 - optional, 1084
 - recommended, 1082-4
- diaper(s)/briefs (adult), 666
 - disposable, 565, 666
 - men, 565
 - older people, 666, 669-70
 - reusable, 669-70
- "diaper" dermatitis, 667
- diaphragms, intravaginal, bladder neck-supporting, 607, 609
- diarrhoea, 990-1
 - antibiotic-associated, 1029
- dicyclomine, 493
- dietary factors
 - FI, 1014-15
 - children, 1022-3
 - older people, 1028
 - UI
 - men, 556
 - women, 576-7
- digital examination/palpation
 - children, rectum, 383
 - male, rectum, 380
 - older people with FI, 1029, 1030
 - pelvic floor muscles, 384
- disabilities
 - associated with childhood FI, 1024
 - physical, *see* functional impairment
- disease, *see* illness; medical conditions
- disposable absorbent products, *see* absorbent products
- diuresis, nocturnal, older people, 633
- diuretics (for nocturia)
 - men, 563
 - older people, 632-3
- diurnal enuresis, *see* daytime wetting
- diverticula, urethra (women), 455-6, 845-6
 - examination for, 380
 - imaging, 455-6, 811
 - treatment, 846
- doctors/physicians
 - family, *see* family doctors
 - hospital, education, 946
- documentation of UI, *see* voiding record
- dopamine and micturition, 122, 123
- dorsal clitoral nerve stimulation
 - sacral reflex recording, 414
 - SEP recording, 412
- dorsal commissure (DCM), 116, 117
- dorsal penile nerve stimulation
 - sacral reflex recording, 414
 - SEP recording, 412, 412-13
- dorsal root ganglion (DRG) and its neurones
 - Na⁺ channels, 140-1
 - in spinal cord injury, 137, 141
- double blind trials, 1053
- double incontinence (faecal and urinary)
 - nursing home residents, 992
 - prevalence in England, 988
- doxazosin, 494
- drainage bags, 675-6
- dribbling
 - definition, 1080
 - post-micturition, men, 561-2, 1090
- drug history, 1081
- drug-induced incontinence
 - AI, 1028
 - UI, 636-7
 - enuresis in men, 557
 - older people, 636-7

drug therapy, 104, 479-511, 728-39, 1072-3
 costs, 974-5
 cost-effectiveness analysis, 978
 day and night-time enuresis, 543
 FI, 1009-10
 children, 1024
 neurological patients, 1013
 men, 562-3
 nocturia, 562-3
 storage symptoms, 562
 neurogenic UI/bladder, 728-39
 children, 545
 nocturia
 men, 562-3
 older people, 632-5
 nocturnal enuresis, 496, 528, 530-1
 non-responders, 531
 older people, 659-61
 behavioural therapy combined with, 656
 nocturia, 632-5
 overactive bladder, *see* bladder overactivity
 post-prostatectomy UI, 561
 research and trials, 502-3, 661, 737, 1072-3, 1113
 storage symptoms, men, 562
 stress incontinence, *see* stress incontinence
 stress incontinence surgery outcome and, 838
 women, 592
 bladder training vs, 601, 602-3
 bladder training with, 603-4
 with BOO, 845
 electrical stimulation vs, 592
 pelvic floor muscle training vs, 583, 602-3
 psychotherapy vs, 602-3
 "Dry Anticipations" project, 943
 dry bed training, 534-5
 "Dry Expectations" project, 944
 "Dry Pants Day" (New Zealand), 943
 dryness, children
 bladder outlet reconstructions for, 770-1
 daytime, epidemiology, 174-5
 duloxetine, 499
 Dutch studies/education etc., *see* Netherlands
 dynamic MRI (incl. ultrafast image acquisition), 443-4
 overactive bladder pelvic organ prolapse, 250, 251
 stress incontinence, 226-7
 dynamic urethroscopy, 458
 dyspareunia, stress incontinence surgery, 837
 Dysport® 900IE, *see* botulinum toxin A

E

economic issues, *see* cost
 ectoATPase, 111
 ectopic ureter, 759
 endoscopy, 459
 imaging, 428
 ectopic ureterocele, 759
 education
 child
 on reasons for soiling, 1022
 at school, and toilet facilities, 1021
 patient, intermittent catheterisation, 711, 714-15
 professional, *see* professional education
 public, *see* public education
 Effect of Urinary Incontinence on Sexual Activity Questionnaire, 287
 Effect of Urinary Incontinence on Sexuality Questionnaire, 287
 efferent neurones, 98-9
 in aging, function, 134
 efficiency (in delivering services), 967

EISQ (questionnaire), 287
 elastase and stress incontinence, 466
 elastin, bladder wall, 37, 38
 elderly, *see* older people
 electrical brain mapping, 413
 electrical properties
 bladder wall smooth muscle, 27-9, 27-30
 urethral smooth muscle, 57
 electrical stimulation, 586-92, 737-41
 anterior sacral root, *see* sacral nerve roots
 bladder (intravesical electrical stimulation), 741-4, 867
 results, 742-3
 SEPs recorded on, 413-14
 bladder activity and effects of repetitive nerve stimulation, 98
 day and night-time enuresis, 542
 in detrusor overactivity, *see* detrusor overactivity
 in FI, 1012-13, 1018
 neuromodulation by, *see* neuromodulation
 in neuropathic UI, 702, 867-8
 older people, 647-8, 650-1
 pelvic floor (in general), 740-1
 pelvic floor, men, 564
 post-prostatectomy, 560-1
 pelvic floor, women, 586-92, 615
 drug therapy vs, 592
 literature search strategies, 617-18
 methods of electrical stimulation, comparisons, 591-2
 no treatment/control treatment vs, 589
 pelvic floor muscle training vs, 582-3, 591, 593-4, 615
 pelvic floor muscle training with, 591
 placebo vs, 589-90
 perception/sensation tests, 412
 bladder, during cystometry, 410-11
 sacral reflexes recorded on, 414, 415
 urethra, SEPs recorded on, 413-14
 electrocoagulation, fistula, 850
 electrodes in neurophysiological tests, 392
 electromyography/surface electromyography (EMG), 320, 346-7, 393-4, 394-407
 abnormalities, interpretation, 346-7
 anal sphincter, *see* anal sphincter
 in clinical disorders, 404-7
 concentric needle, *see* concentric needle electromyography
 enuresis, pelvic floor, 522
 good urodynamic practice, 347
 indications, 320, 347
 kinesiographical, 395-6
 pathological correlates, 393-4
 postpartum (pelvic floor), 219
 FI and, 1002-3
 predictive value, 347
 research recommendations, 418
 single fibre, 402-4
 smooth muscle, 416
 study results, description, 346
 technical aspects, 346
 see also biofeedback
 electroneurography, dorsal sacral roots, 412
 electrophysiological studies, *see* neurophysiological studies
 electrostimulation, *see* electrical stimulation
 emeprium bromide, 660
 EMG, *see* electromyography
 emotional disorders, overactive bladder, 142-3
 encopresis, definition, 1019
 see also soiling
 endocrine disease, nocturnal enuresis, 557
 endopelvic fascia, *see* fascia
 endoscopic surgery
 detrusor instability (women), 846-7
 rectourethral fistula approach via, 805

endoscopy (cystoscopy/cystourethroscopy), 457-60, 467, 1084
 men, preoperative, 788
 recommendations and research areas, 460, 1084
 women with BOO, 844

enemas
 antegrade colonic (Malone's), 1019, 1024
 older people, 1031
 "Therevac" micro enemas, 1013

energetics, smooth muscle, 107-8

English-speaking populations, ICIQ, 302

enterocele, 447
 definition, 253
 MRI, 447
 repair, 253

enterocystoplasty, *see* bowel

enuresis (wetting), 169-75, 518-44, 1086
 adults, 173
 male, 556-7
 definitions, 169, 326, 523, 1080
 diurnal/daytime, *see* daytime wetting
 evaluation, 518-23
 urodynamic studies, 358, 521-3
 nocturnal, *see* nocturnal enuresis
 risk factors, 170-3
 services (children), 957
 therapy, 528-35
 non-responders, 531

enuresis alarm, 529-30, 532-3
 daytime wetting, 542
 desmopressin and, 530-1
 non-responders, 531

Enuresis Resource and Information Centre (ERIC), 964

EORTC metastatic prostatic cancer (questionnaire), 283

ephedrine
 post-prostatectomy UI, 561
 stress incontinence, 498

EPICONT study, 180

epidemiology, 165-202
 AI/FI, 988-92
 child, 1019
 older people, 1025-6
 analytical, 167
 definitions in, 168-9
 descriptive, 167
 obstetric fistulas, 898-902
 pelvic organ prolapse, 246-9, 258
 UI (in general), 165-202
 basic considerations, 167-9
 clinical work and, 193-4
 research recommendations, 194-5
see also specific epidemiological factors e.g. prevalence; risk factors
 epididymitis/epididymo-orchitis with intermittent catheterisation, 713, 714

epidural analgesia, labour, 219

episiotomy, 219-20, 1008

epispadias, 759, 797-9
 day or day/night wetting, 174
 management of persisting incontinence (later life), 797-9, 813

epithelium, *see* mucosa; urothelium

EQ-5D, 280-1

equity (in economics), 967

equivalence trials (and equivalence in trials), 1050, 1054, 1111

erectile dysfunction, penile biothesiometry, 411

erosions, urethral, with artificial urinary sphincter, 806-9, 812

error
 observer, 1053
 type II/beta, 1051

Escherichia coli and intermittent catheterisation, 713

Ethiopia, continence services, 957

ethnicity, *see* race

Europe, maternal mortalities, 897

EuroQoL, 280-1

evacuation proctography, *see* defaecography

evoked potentials
 brain mapping techniques, 413
 correlation with pathology, 393
 motor, 409, 409-10
 somatosensory, 412-14

examination, *see* physical examination

excitation-contraction coupling, detrusor, 33-5, 110-12

excitatory junction potentials, bladder, 29

exclusion criteria, trials, 1048, 1052-3, 1111

exercise
 anal sphincter, in FI treatment, 1010
 pelvic floor, *see* pelvic floor muscle training
 physical, strenuous, *see* physical exercise

explanatory trials, 1055

exstrophy, *see* bladder exstrophy; cloacal exstrophy

extra-urethral occluding devices
 female, 610-12
 male, 565

extra-urethral UI, 319
 endoscopy, 459
 fistula causing, *see* fistula

F

FACT-G and FACT-P form, 283-4

faecal incontinence (anal incontinence), 71, 985-1043, 1108-9
 assessment/investigations, 998-1002, 1108
 associated conditions/situations, 989-91
 causes/risk factors, *see* aetiology
 definitions, *see* definitions
 epidemiology, *see* epidemiology
 grading and scoring, 994-5
 management, 221-2, 1009-19, 1108-9
 children, 1022-4
 conservative, *see* conservative management
 older people, 1030-3
 severe FI, 1108
 surgical, *see* surgery
 older people, *see* older people
 paediatric, *see* children
 pathophysiology, 996-8
 ageing and, 1026-7
 pelvic organ prolapse and, 248
 postpartum, *see* childbirth
 professional education and awareness, 988
 QoL, 995-6
 services for people, 987

Faecal Incontinence QoL Scale, 995

Faecal Incontinence Severity Index, 994

faeces
 discharge, *see* defaecation; defaecography; encopresis; soiling
 impaction in children, management, 1024
 impaction in older people, 637, 1027-8
 management, 1031
 loose, older people, 1029
 manual evacuation, 1014
 retention/holding, functional, 1020

falls and incontinence, 976

family doctors, 955-6
 education, 946-7

family history
 enuresis
 day and day/night, 174
 nocturnal, 170-2
 UI, as risk factor for development, 187

- family life, African women with obstetric fistulas, 912-13
- fascia
- iliococcygeus, attachment, 252, 258
 - pelvic/endopelvic, 66-8, 68-9, 69
 - fixation, 252, 258
 - tendinous arch (arcus tendineus) of, 68
 - rectovaginal, attachment, 261
- fascial slings
- children, 770
 - men, 812-13
- fast twitch muscle fibres in pelvic floor muscle training, 580
- fat pad graft, obstetric fistulas, 921
- FDA on anti-incontinence device studies, 1071-2
- females, 222-8, 571-624, 823-63, 1064-6, 1094-9
- bladder
 - anatomical relations to other structures, 20-2
 - endoscopy, 458-9
 - bladder neck
 - anatomy, 50
 - endoscopy, 458
 - open, imaging, 454
 - conservative management, 571-624
 - anti-incontinence devices, *see* anti-incontinence devices
 - BOO, 845
 - catheters, older women, 672
 - of non-obstetric fistulas, 850
 - pelvic organ prolapse, 251, 1098
 - epidemiology of UI, 175-88
 - imaging of LUT, 431-50, 467
 - LUTS, *see* lower urinary tract symptoms
 - menopausal/postmenopausal, *see* menopausal women
 - pathophysiology of UI, 217-28
 - pelvic floor disorders/dysfunction/prolapse, *see* pelvic floor; pelvic organ prolapse
 - PET scans of brain, and pelvic floor motor control, 125
 - physical examination, *see* physical examination
 - pressure-flow studies
 - in obstruction, 343-4
 - predictive value, 345-6
 - questionnaires and clinical measures in, relationship between, 273
 - recommended management, 1094-9
 - risk factors for and causes of UI, 182-7, 205
 - severity of UI and symptoms, *see* severity
 - sexual function/satisfaction assessment, 287, 1066
 - stress incontinence, *see* stress incontinence
 - surgery, *see* surgery
 - urethra
 - anatomy, 52-3
 - diverticula, *see* diverticula
 - urethral resistance, 109
 - urethral sphincter anatomy/location, 52, 222-3
 - urge incontinence in, *see* urge incontinence
 - urinalysis, 465
 - urinary retention, concentric needle EMG, 406-7
 - urodynamic studies, 353-5, 1094
 - in BOO, 843
 - pressure-flow studies, *see subheading above*
 - urogenital diaphragm, 222-3
 - see also* childbirth; girls; pregnancy
- FemAssist, 611-12, 614
- FemSoft, 612, 613, 614
- fenestrated capillaries, bladder, 39
- fertility and obstetric fistulas, 912-13
- fetus, micturition control, 515
- fibre, dietary (and possible contribution to FI), 1014-15
- children, 1022
 - older people, 1028
- fibrillin, 38
- fibrosis
- bladder, *see* bladder
 - vaginal, salt-packing producing, 901
- filling of bladder, *see* bladder, filling; cystometry
- financial issues, *see* cost
- fistula, men, 802-6, 813
- fistula, women, urogenital, 893-935
- non-obstetric, 849-53
 - children, 759
 - clinical features, 850
 - post-gynaecological surgery, 837, 850
 - treatment, 850-3, 854
 - obstetric (in developing world), 184, 893-935, 1094
 - classification, 914-16
 - complicated cases, 924-7
 - early care, 916
 - endoscopy, 459
 - epidemiology, 898-902
 - levels of evidence concerning, 896
 - maternal mortality and, 896-8
 - origins and consequences, 899
 - prevention, 927-8, 957
 - social consequences, 912-14
 - surgery, *see* surgery
- flap(s)
- bladder contractility-increasing, 868
 - muscle, *see* muscle flaps
 - obstetric fistula repair, 917
 - urethral lengthening, children, 771
 - urethral reconstruction
 - with non-obstetric fistulas, 853
 - with obstetric fistulas, 925
 - urethral sphincter resistance-increasing, 879-80
- flap valve theory of FI, 996
- flavoxate, 493-4, 732
- older people, 660
- flow, *see* urine flow
- fluid intake
- children, and FI, 1022
 - men, 556
 - older people, 637
 - and FI, 1028
 - women, 576
- fluoroscopy
- pelvic organs, 449
 - prolapse, 249, 250, 449
 - in videourodynamics, 347-8, 349
- flurbiprofen, 495
- flutter valve theory of FI, 996
- follow-up, 1062
- artificial urinary sphincter, consensus protocol for, 812
 - time, in trials, 1055
 - pelvic organ prolapse, 255
- Food and Drugs Administration on anti-incontinence device studies, 1071-2
- foot-drop, 910
- forceps delivery, effects, 1008
- forebrain and micturition, 123-4
- four corner suspension, 254
- fracture
- incontinence associated with, 976
 - pelvic, open bladder neck, 454
- frail elderly persons, 727, 1067-8, 1104-7
- causes of incontinence, 638-9
 - definition of frailty, 627
 - LUT dysfunction, outcome measurement, 646-7
 - physical examination, 387
 - preoperative evaluation, 661
 - recommended management, 1104-7
 - men, 1104-5
 - women, 1106-7
 - research, 1112
 - on outcome, 1067-8
 - urodynamic studies, 359-60

France
 costs of UI, 973
 prevalence of AI, 989
 public awareness campaigns, 944
 free radical damage, 133
 frequency (=frequency of micturition), developing child, 517
 frequency (=frequent micturition)
 daytime, and paediatric bladder instability, 527
 electrical stimulation, women, 589
 nocturnal, older people, drug therapy, 633-4
 frequency/volume chart (bladder chart), 378-9, 1114-16
 child, 519
 instructions for using, 1114
 standard 7 day versions, 1115, 1116
 frequency/volume diary (bladder/voiding diary), 270, 1060, 1112, 1114-15
 children, 519
 instructions for using, 1114
 men, preoperative, 788
 older people, 641, 642, 643, 645, 646, 648
 standard 7 day versions, 1115, 1116
 women with BOO, 842-3
 frontal lobe damage, defaecation in, 997
 frusemide (furosemide), nocturia
 men, 563
 in older people, 633
 fulguration, fistula, 850
 Functional Assessment of Cancer Therapy and Prostate Form, 283-4
 functional disorders of LUT, *see* lower urinary tract dysfunction
 functional faecal incontinence
 children
 functional non-retentive soiling, 1020, 1020-1
 functional retentive soiling, 1020
 older people, 1029
 functional faecal retention, 1020
 functional impairment (mobility restriction; physical disability), 1067-8, 1104-7
 FI with, older people, 1028
 outcomes research, 1067-8
 recommended management, 1104-7
 older men, 1104-5
 older women, 1105-6
 UI prevention in older people, 678
 UI risk, 678
 men, 190
 older people, 637, 643, 678
 women, 186-7
 functional outcomes in prolapse surgery, evaluation, 376
 functional urinary incontinence (i.e. in older people), 638-9
 funding
 continence services, 957-8
 professional education, 951
 furosemide, *see* frusemide

G

GABA (gamma-aminobutyric acid), micturition and, 122
 parasympathetic preganglionic neurones and, 120
 galanin distribution (and its detection), 100, 101, 102
 gamma-aminobutyric acid, *see* GABA
 ganglia, *see* autonomic ganglia
 gastric augmentation, *see* stomach
 gastrointestinal tract
 disorders
 intestinal segment removal causing, 776-7
 pelvic organ prolapse and, 247
 reconstruction using, *see* neobladder
 see also specific regions

gender
 nocturnal enuresis prevalence and, 525
 urge incontinence and depression and, 143-4
 see also females; males
 gene(s), LUT function and role of, 144
 gene therapy, 737
 general hospitals, fistula units, 929
 genetic factors (in disease), 146
 nocturnal enuresis, 170-2, 524-5
 UI, 187
 genitalia
 child, physical examination, 761
 female
 injury in obstructed labour, 906-8
 mutilation, 901-2
 physical examination, 379
 see also gynaecological surgery
 genitourinary complications, intermittent catheterisation, 713-14
 genitourinary fistula, *see* fistula
 Germany, continence organisation, 963
 Ghana, obstetric fistulas, 900
 giggle incontinence, 540
 Gilliam procedure, 252
 girls
 bladder capacity, 516
 bladder reconstruction and later pregnancy, 778
 nocturnal enuresis prevalence, 525
 physical examination, 383
 vesicovaginal entrapment, 540
 see also children
 gishiri-cutting, 901
 global issues, *see entries under* international
 glutamate, micturition and role of, 116, 117, 118, 122
 glycine and parasympathetic preganglionic neurones, 116
 glycoproteins, microfibril-associated, 38
 GMP, cyclic (cGMP), 114
 interstitial cells of Cajal and, 102-3
 urethral contraction and, 57-60
 cGMP-dependent protein kinase I, 144
 Golombok--Rust Inventory of Sexual Satisfaction, 285-6
 Gore-Tex for slings, 831
 Göteborg QoL Instrument, 281
 GQL (Göteborg QoL Instrument), 281
 gracilis muscle flaps
 for FI, 1017
 urethral reconstruction with obstetric fistulas, 925
 urethromyoplasty, 879-80
 grafts
 autologous, *see* autologous grafts
 interposition, vesicovaginal fistula, 852-3
 obstetric fistulas, 917
 for suburethral sling, 831
 urothelial, *see* urothelium
 growth, enterocystoplasty effects on, 778
 growth factor and overactive bladder, 126
 see also nerve growth factor
 gynaecological injury in obstructed labour, 906-8
 gynaecological surgery, urogenital fistulae following, 837, 850

H

haemorrhage, *see* bleeding
 haemoxygenase-2 (HO-2) distribution (and its detection), 100, 101
 Hald, Tage, 9
 health insurance, 967
 health professionals, *see* professional education
 health-seeking behaviour, triggers for, 944-5
 health status questionnaires (health-related QoL), 279-81, 1062
 recommended, 306
 HealthSTAR, 269

- help-seeking behaviour, 192-3
- heredity, *see* genes; genetic factors
- Hirschsprung's disease, 1020
 - investigations indicated, 1021
- histochemistry, autonomic nervous system, 100
 - see also* immunohistochemistry
- history-taking, 378, 1081-2
 - children, 759-61, 1086
 - enuresis, 518
 - FI, 1021
 - disabled people, 1067-8
 - FI, 998-9, 1108
 - children, 1021
 - older people, 1029
 - neuropathic LUT dysfunction, 1070
 - obstetric, 1065
 - older people, 642-3, 645
 - frail, 1067-8
 - in urodynamic findings prediction, 328
- Holland, *see* Netherlands
- home, evaluation of older people in, 643
- home training (nocturnal enuresis), full spectrum, 535
- Hong Kong Continence Society, 963
- hormone therapy, *see* oestrogen; progestins
- hormone (oestrogen) replacement therapy, 185, 635
 - FI and, 1010
- hospitals
 - accounting systems, 971
 - general, fistula units, 929
- hydrogel-coated indwelling catheters, 719, 719-20
- hydronephrosis, imaging, 428
- hydrophilic catheters, 709-10
 - complications, 714
- hydrostatic pressure, bladder distension using, *see* cystodistension
- 5-hydroxytryptamine, *see* serotonin
- hyoscyamine, *see* atropine
- hyperchloraemic acidosis, 776
- hypersensitivity disorders and, detrusor overactivity, 210-11
- hypertension, rat models, 137-9
- hypnotherapy, nocturnal enuresis, 532
- hypogastric nerves, 24
- hypothalamus, 123
- hysterectomy
 - continence surgery combined with, outcome, 839-40
 - for pelvic organ prolapse, 247
 - pelvic organ prolapse following, 246
 - management, 252
 - as risk factor for UI, 185-6, 682
 - preventive strategies in older women, 682

I

- "I will manage" program, 942-3
- iatrogenic damage
 - rectourethral fistula due to, 803
 - stress incontinence surgery, 836-7
 - see also* Injury
- ice water test, 355, 411
- ICIQ, 274, 299-305, 1059
 - developing, 299-305
 - short form (ICIQ-SF), 269, 274, 299, 1083, 1117
 - Japanese version, 302
 - UK version, 302
- ICS (International Continence Society)
 - Continence Promotion Committee, 959, 1110
 - educational materials, 951
 - Standardisation Committee, on research methodology and terminology, 1047
- ICSmale and ICSmaleSF, 278

- ICSQoL, 283
- ICSSex, 286
- IIQ, *see* Incontinence Impact Questionnaire
- ileocaecal valve, 773-4
- ileum
 - alternative continence channel construction with, 773
 - neuropathic patients, 882
 - cystoplasty using
 - cancer complications, 778
 - child, 765-6
 - intestinal complications, 776
 - metabolic complications, 776
 - neuropathic patient, 881
- iliococcygeus, 66
- iliococcygeus fascia attachment fixation, 252, 258
- illness, costs of, 969, 1063
 - definition, 969
 - global, 972-3
 - measurement, 969, 1063
 - see also* disabilities; medical conditions
- imaging, 427-57, 1083, 1084
 - childbirth-related changes/trauma, 224, 445
 - children, 761-2
 - CNS, 456-7, 467, 468, 1084
 - FI, 1001-2
 - men
 - post-prostatectomy UI, 451
 - preoperative, 788
 - neurogenic LUT dysfunction/incontinence, *see* neurogenic LUT dysfunction
 - pelvic floor dysfunction (women), 431-50, 467
 - pelvic organ prolapse, 249-51, 446
 - special issues, 452-6
 - stress incontinence, *see* stress incontinence
 - upper urinary tract, *see* upper urinary tract
 - urethral diverticulum, 455-6, 811
 - urodynamics and, *see* videourodynamics
 - see also specific modalities*
- imipramine
 - nocturia
 - men, 563
 - older people, 660
 - nocturnal enuresis, 531
 - overactive bladder, 495
 - stress incontinence, 498-9
- immunohistochemistry and immunocytochemistry
 - autonomic nervous system, 100
 - myofibroblasts (in detrusor), 103
- imperforate anus, 357, 1020
- impotence (erectile dysfunction), penile biothesiometry, 411
- incidence
 - definition, 168
 - faecal incontinence, 988-92
 - in women of UI, 180-2
- inclusion criteria, trials, 1048, 1052-3, 1111
- InContact, 964
- incontinence
 - definitions of FI, 987
 - child, 1019
 - definitions of UI, 168, 327
 - children, 169
 - older people, 628
 - urodynamic, 326, 327
 - measurement/assessment, 270-4, 1081-4
 - highly recommended tests, 1081-2
 - non-recommended tests, 1084
 - optional tests, 1084
 - recommended tests, 1082-4
 - severity, *see* severity
 - types, 168
 - women, 176-8

incontinence devices and products, *see* anti-incontinence devices
 Incontinence Impact Questionnaire (IIQ), 273, 282-3, 289
 modified versions, 283
 Incontinence QoL (I-QoL) index, 282
 sexual aspects, 288, 289
 Incontinence Severity Index, 278
 Incontinence Stress Index, 278
 independence, absorbent pad users, 668
 Indian Continence Foundation, 963
 Indiana system/pouch/reservoir, child, 767, 774
 indomethacin, 495-6
 Indonesian Continence Society, 963
 infants (incl. neonates)
 bladder/sphincter control, development, 515-16
 urodynamics, 358-9
 infections
 skin, economic issues, 976
 urinary, *see* urinary tract infections
 wound, in stress incontinence surgery, 837
 infertility and obstetric fistulas, 912-13
 infibulation, 902
 inflammatory mediators, bladder afferents and, 90
 In-Flow device, 605-6
 informed consent (in trials), 1053
 Ingelman-Sundberg denervation, 875-7
 women, 848
 inheritance, *see* genes; genetic factors
 injection
 botulinum toxin, *see* botulinum toxin
 denervating agents, *see* bladder, denervating agents
 perianal biomaterials, 1018
 periurethral bulking agents, *see* bulking agents
 injury (trauma)
 bladder
 in obstructed labour, 904-6
 prostatectomy-related, *see subheading below*
 with stress incontinence surgery, 836
 cauda equina, *see* cauda equina lesions
 childbirth-related, *see* childbirth
 nerve, *see* nerve injury
 pelvic floor, men, incontinence after, 797, 813
 pelvic plexus, 700
 prostatectomy-related (to bladder/urethra), 232-3
 causes, 232
 urodynamic studies, 233, 353
 renal, with obstructed labour, 906
 spinal, *see* spinal cord, lesions
 ureteric, with obstructed labour, 906
 urethral, 797
 incontinence after, men, 797
 with indwelling catheters, 721
 with intermittent catheterisation, 713-14
 with obstructed labour, 905-6, 924-6
 prostatectomy-related, *see subheading above*
 with stress incontinence surgery, 836
 vaginal, *see* vagina
 visceral, with stress incontinence surgery, 836
 see also fracture
 innervation, *see* nerve supply
 inserts, *see* liners
 instability, *see* bladder instability; urethra, unstable
 institutional care (elderly), *see* nursing home
 instrumental delivery, effects, 1008
 insulin-like growth factor-binding proteins, 144
 insurance, health, 967
 intellectual impairment, *see* cognitive impairment
 intercellular coupling, detrusor smooth muscle, 114

interference patterns, concentric needle EMG information, 399-400
 intermittent catheterisation, 702, 708-17
 adjunctive therapy, 711
 children, 542, 1088
 cost-effectiveness, 716-17
 education, 711, 714-15
 frequency, 711
 older males, 673
 safety aspects, *see* safety aspects
 self-catheterisation, *see* self-catheterisation
 stopping, reasons, 716
 techniques and materials, 709-11
 women with BOO, 845
 International Consultation on Incontinence, *see* ICI
 international continence organisations, 958-60, 1110
 International Continence Society, *see* ICS
 International Foundation for Functional Gastrointestinal disorders, 964
 international issues (global/worldwide issues)
 cost of illness, 972-3
 questionnaires, 272, 298
 ICIQ, 302
 Internet, education resources, 951-2
 interneurons, sacral spinal cord, 115-17
 interposition grafts, vesicovaginal fistula, 852-3
 inter-sphincteric groove, 71
 interstitial cells (urinary tract wall), 101-3
 of Cajal, 102
 cells like, 103
 interstitial radiotherapy, *see* brachytherapy
 interstitial tissue (bladder wall), 38
 intestine, *see* bowel
 intraurethral (occluding) devices, 612-14, 616
 intravaginal bladder neck support devices, 607-10, 616
 intravaginal resistance devices, 584-6
 intravenous urography/pyelography, 428
 intravesical electrical stimulation, *see* electrical stimulation
 intravesical pressure (bladder pressure)
 bladder expression technique increasing, 706
 difference between urethral pressure and, *see* urethral closure pressure
 with involuntary leakage of urine, *see* leak point pressure
 measuring, 323
 child, 517
 urine flow rate and, relationship, *see* pressure--flow studies
 intrinsic sphincter deficiency, *see* urethral sphincter
 introital sonography, 436, 441
 Introl, 607, 608
 invasive diagnostic procedures, enuresis, 520-3
 ion channels, *see specific ions*
 I-QoL, *see* Incontinence QoL index
 IQOLI (questionnaire), sexual aspects, 288
 irritable bowel syndrome, postpartum, 1009
 ischaemia, bladder, 130
 obstructive dysfunction and, 132-3
 ISI (Incontinence Stress Index), 278
 ISO 11948-2, 667
 isotopic scans, upper urinary tract, 430-1
 Israel, services in, 954-5, 956
 National Center for Continence, 954-5, 963
 Italy, costs (of UI), 973
 routine care, 974

J

Japan
 needs of service users, 953
 specialist nurses, 949
 Japan Continence Action Society, continence awareness materials, 943

Japanese ICIQ-SF, 302
jejunum in bladder reconstruction, child, 766

K

kappa opioid receptor, 117
agonists, 96, 99, 117
Kegel's exercises, *see* pelvic floor muscle training
Kelly-type anterior repair, 826, 827
kidneys
function
assessment, 1083
indwelling catheters and, 721
intestinal reservoirs and, 776, 777
prosthetic bladders and protection of, 884
imaging, 428
enuresis, 520
injury with obstructed labour, 906
stones, indwelling catheters and, 722
kinesiological EMG, 395-6
King's Health Questionnaire, 276-8
sexual aspects, 287, 288
Kock pouch
child, 767, 774
complications, 777
Korean continence organisations, 963-4
Kropp procedure, 773

L

L region (pontine micturition centre), 121
labour
epidural analgesia, 219
obstructed, 902-14
causes, 901-2
injury associated with, 902-14
pathophysiology, 902-3
social consequences, 912-14
see also childbirth
lactose intolerance, older people, 1029
lamina propria, urethral, 55, 63
structure, 63
vascular filling, 63
language in questionnaires, *see* international issues
laparoscopic colposuspension, 828, 829, 835
lateral collateral pathways (LCPs) of Lissauer's tract, 91, 116
latex allergy
condom catheters, 727
indwelling catheters, 722
Latin America, maternal mortality, 897
latissimus dorsi flaps, 868
Latzko procedure
rectourethral fistula, child, 804, 805
vesicovaginal fistula, non-obstetric, 851
laughter incontinence (children), 540
laundry issues, absorbent products, 671
laxatives
children, 1024
neurological patients, 1013
older people, 1031
overuse, 1029
lazy bladder syndrome, 539, 542
leak point pressure, 337-41
abdominal, *see* abdominal leak point pressure
abnormalities, interpretation, 338-9
in coughing, 338
detrusor, *see* detrusor leak point pressure
future study areas, 341
good urodynamic practice, 340
indications for measurement, 339-40

leak point pressure – cont'd
men, preoperative, 788-9
predictive value, 341
study results, description, 338
technical aspects, 338
Valsalva, *see* Valsalva manoeuvre
leakage of urine, 460-4
bladder pressure with involuntary leakage of, *see* leak point pressure
condom catheters and, 726
continuous, 1080
detection methods, 324, 460-4
with indwelling catheters, 721
marking, in leak point pressure measurement, 340
in overdistended bladder (=overflow incontinence), drug therapy, 499-500
with pads
insert pads, 668
performance tests, 668
leg bags, 675-6
levator ani muscles, 66
denervation/reinnervation, and stress incontinence, 467
EMG, 395
female
damage in childbirth, 223-4
myorrhaphy, 258
hiatus
MRI, 446, 447
ultrasound, 441
male, 230
strength assessment, 384
levels of evidence
epidemiological studies, 168
imaging, 427
obstetric fistula, 896
lidocaine for overactive bladder in BPH, 141
lifestyle, absorbent pad users, 668
lifestyle interventions
men, 533-4
women, 573-8, 614-15, 1094
literature search strategies, 617
research recommendations, 617
ligaments (pelvic region), 69
cardinal, *see* cardinal ligaments
pubourethral, female, 222
sacrospinous, suspension, 252, 258
uterosacral, *see* uterosacral ligaments
lignocaine (lidocaine) for overactive bladder in BPH, 141
liners (inserts; shields), 564
leakage, 668
older people, 665-6
liquid filling medium for cystometry, 329
Lissauer's tract, 91
lateral collateral pathways of, 91, 116
medial collateral pathways of, 91
lithotomy position, high, obstetric fistula repair, 917
long-term care institutions, *see* nursing home
loperamide, 1009
older people, 1031
lower motor neurone lesions, *see* conus, lesions
lower urinary tract
anatomy and cell biology, 17-82
central pathways controlling, *see* central nervous system
connective tissue, *see* connective tissue
gens in functional regulation of, 144
imaging, *see* imaging
innervation, *see* nerve supply
modulatory systems, 64-5
obstruction, *see* bladder obstruction; bladder outlet obstruction; obstruction

lower urinary tract dysfunction
 children
 UI due to, 526
 urodynamics, 358-9
 neurogenic, *see* neurogenic LUT dysfunction
 neurophysiological tests in, 417
 older people/elderly, outcome measurement, 646-7
 pelvic organ prolapse comorbid with, 247-8, 835-6
 two types, 319
 lower urinary tract symptoms, 1058-66
 men
 endoscopy, 459
 outcomes research, 1064
 as risk factor for UI, 189-90
 women, 1064-6
 outcomes research, 1064-6
 as risk factor for UI, 186
 lubricants
 for faecal impaction, 1024
 for urethral catheters, 709
 lumbar spine, imaging, 456, 467
 lumbar sympathetic outflow, 99

M

McCall culdeplasty, 252, 258
 Macroplastique, 833
 magnetic brain mapping, 413
 magnetic resonance imaging (MRI), 442-50
 CNS, 456-7
 dynamic, *see* dynamic MRI
 FI, 1002
 indications, 447-9
 pelvic floor dysfunction, 442-50, 467-8
 methodology, 443-4
 other imaging modalities compared, 433, 438, 449-50
 pelvic organ prolapse, 250-1, 446, 447-9
 of anatomical changes, 446
 in grading of relaxation, 446-7
 standardisation of anatomy, 444-7
 stress incontinence, 226-7, 447
 three-dimensional, 444
 upper urinary tract, 430
 urethral diverticula, 455-6
 magnetic stimulation
 brain, 409
 pelvic region, 410-11
 sacral reflexes recorded, 414
 Mainz pouch, child, 764, 767, 774
 Malaysia, Continence Foundation, 964
 male(s), 230-4, 553-69, 785-821, 1064, 1090-3
 bladder anatomy, 21
 neck, 52
 relations to other structures, 22
 bladder outlet endoscopy, 459-60
 catheters, older men, 672
 causes or and risk factors for UI, 189-91, 205-6
 prostatectomy, *see* prostatectomy
 conservative treatment, 533-69
 anti-incontinence devices, 564-5, 674-5, 676
 epidemiology of UI, 188-91
 erectile dysfunction, penile biothesiometry, 411
 LUTS, *see* lower urinary tract symptoms
 nocturia in men, drug therapy, 562-3
 PET scans of brain, micturition studies, 125
 physical examination, 380-1, 387

male(s) – cont'd
 questionnaires in
 clinical measures and, relationship between, 272-3
 severity of UI, 278
 validated, 305
 recommended management, 1090-3
 frail and/or disabled older men, 1104-5
 sexual function/satisfaction questionnaires, 286
 validated, 305
 surgery, *see* surgery
 urethra, 54, 55
 anatomy, 55, 230
 membranous, 55
 prostatic, 55
 spongy/penile, 55
 urethral resistance, 109
 urge incontinence, *see* urge UI
 urodynamic studies, *see* urodynamic studies
 see also boys
 male guards, 666
 malignancy, *see* bladder cancer; prostate cancer
 Malone's antegrade colonic lavage/enema, 1019, 1024
 Manchester procedure, 252
 manometry, anorectal, 999
 children, 1021-2
 manual evacuation of bowel, 1014
 marriage, African women with obstetric fistulas, 912-13
 Marshall--Marchetti--Krantz (MMK) procedure, 827
 injury in, 836
 Martius flaps/grfts, fistulas
 non-obstetric, 851
 obstetric, 917, 921
 maximum cystometric capacity, child, 522
 maximum urethral closure pressure, *see* urethral closure pressure
 maximum urethral pressure (MUP), α -agonists increasing, 110
 Mayo bladder, 884
 measurement of UI, *see* incontinence
 mechanical stimulation
 pudendal cerebral SEP on, 413
 sacral reflexes on, 414, 415
 mechanics
 detrusor, 27
 urethral smooth muscle, 57
 medial collateral pathways of Lissauer's tract, 91
 medical conditions, pre-existing/comorbid
 AI associated with, 990, 991
 children, 1020
 older people, 1028
 assessment for, 1081
 stress incontinence surgery outcome and, 838
 see also disabilities; illness
 Medical Outcomes Study SF-36, 279-80
 medical professionals
 education, 946-8
 in multidisciplinary care, 956
 medication, *see* drug
 MEDLINE, 269
 medroxyprogesterone acetate
 stress incontinence, 501
 urge incontinence, 501
 medulla (oblongata) and micturition, 121-2
 medullary cone, *see* conus
 membrane
 electrical properties, detrusor, 27-9
 ion channels, *see specific ions*
 transmembrane transport in bladder, 46
 membranous urethra, 55
 men, *see* males
 menopausal/postmenopausal women
 HRT, 185, 635
 risk of UI, 185
 voiding disorders and NO, 64-5
 mental disorders, *see* psychiatric and psychological disorders

mental status, assessment, 1081
Mersilene, 831
meshes, synthetic
 anterior wall prolapse, 260
 sacrocolpopexy, 253
metabolic complications, intestinal reservoirs, 776
metabolism, 107-10
 aging and cellular metabolism, 133-4
 BOO and, 131-2
 connective tissue strength and, 213
 mucosal, 108-9
 smooth muscle, 107-10
 stress incontinence and, 109-10
 unstable bladder contraction and, 131-2
metastatic prostate cancer, QoL questionnaire, 283
methenamine, intermittent catheterisation, 715
methoxamine, 498
metoprolol, 494
micro enemas, "Therevac", 1013
microfibril(s), 38
microfibril-associated glycoproteins, 38
micturition, 115-26
 central pathways controlling, 86, 115-26, 481-2
 imaging studies, 124-5, 457, 482
 serotonin and, 105
 control, development, 515-16, 535
 dribbling after, *see* dribbling
 frequency of, *see* frequency
 see also voiding
micturition reflex (bladder reflex), 86-9
 circuitry/pathways, 115, 119
 central, 121-6
 supraspinal, *see* supraspinal pathways
 in detrusor overactivity, changes, 129-30
 spinal, in BOO, 135
 triggering (triggered reflex voiding), 702, 703-8
micturition time chart, 1114
 instructions for completing, 1114
 see also frequency/volume chart
Miniguard, 611
minimisation (in trials), 1052
minimum data set, 195, 1112
 nursing home residents, 629
mitochondrial metabolism
 bladder hypertrophy and, 131-2
 smooth muscle, 108
Mitrofanoff procedure, 771-3, 882
mixed (urge and stress) incontinence
 definition, 327
 electrical stimulation, women, 590
 older people, 638
 recommended management in women, 1094
 urodynamic studies, 354
 patient history in prediction of findings, 328
 women, 354
mobility, impaired, *see* functional impairment
monoamine(s), micturition and role of, 119
monoamine oxidase inhibitors, 104
Montie procedure, 882
mortality, maternal, obstetric fistulas and, 896-8
Moschovitz operation with colposuspension, 836
motoneurons of external urethral sphincter, 86, 98-9
motor control of pelvic floor, PET studies of brain in, 125
motor evoked potentials, 409, 409-10
motor function evaluation, 383
"motor incontinence" (of faeces), use of term, 987
motor innervation, 65
 bladder, 46-8, 65
 see also efferent neurones
motor neurone lesions
 lower, *see* conus, lesions
 upper, evaluation for, 383-4

motor system, somatic, 392, 394-410
 tests, 394-410
motor unit potentials (MUPs) in concentric needle EMG, 397-9, 401
mucosa
 bladder, metabolism, 108-9
 intestinal, intestinal segments free of, 767-8
mucus from intestinal reservoirs, 775
 infections and, 777
multidisciplinary care, 956, 1110
multiple sclerosis, 700
 incontinence and QoL questionnaires, 288
multiple system atrophy (Shy--Drager syndrome), 700
 EMG studies, 402, 403, 404, 405
 imaging of open bladder neck and urethra, 453-4
multiplicatory scores in questionnaires, 272
multivariate analysis in pelvic organ prolapse treatment trials, 255-6
muscarinic (M) receptors, 484-6
 agonists, overflow incontinence, 500
 antagonists, *see* anticholinergics
 bladder/detrusor, 35, 110, 484-6
 gene knockout studies, 144
 see also cholinergic nerves
muscle(s)
 augmentation
 increasing bladder contractility, 868
 increasing sphincteric resistance, 879-80
 denervation, *see* nerve injury; reinnervated muscle
 excision (myectomy), *see* autoaugmentation
 pathology, neurophysiological parameters correlating with, 393
 primary disease, EMG, 407
 see also pelvic floor muscle; smooth muscle; striated muscle *and*
 specific named muscles
muscle fibres in pelvic floor muscle training, slow and fast twitch, 580
muscle flaps
 bladder contractility increased with, 868
 in FI, 1017
 with obstetric fistulas, 917
 in urethral reconstruction, 925
 urethral sphincter resistance increased with, 879-80
muscle relaxants, *see* bladder relaxants
mycetoma, fistula complicating, 802
myectomy, bladder, *see* autoaugmentation
myelodysplasia, 453
myelomeningocele
 day or day/night enuresis and, 174
 FI, 1020
myofibroblasts, 102-3
myopathies, EMG, 407
myoplasty
 bladder, 868
 urethral sphincter, 879-80
myorrhaphy, levator, 258
myosin and bladder smooth muscle contraction, 24, 112-14

N

National Association for Continence (US), 964
National Center for Continence, Israel, 954-5, 963
national continence awareness campaigns, 942-3
National Institutes of Health, estimates of costs of UI, 972
natural history
 nocturnal enuresis, 183
 pelvic organ prolapse, 248-9
 UI in women, 180-2
NCX gene, 144
need(s), continence service users, 953, 1110
needle suspension (bladder neck), 829-30, 835
 haemorrhage, 836
 older women, 662

- neobladder, orthotopic (reconstruction using gastrointestinal segments), 353, 763-7, 881-3
 - for bladder cancer, 795
 - children, 763-7
 - complications, 775-7
 - neuropathic patients, 874, 881-3
 - women, 848-9
 - see also* bowel bladder surgery using
- neonates, *see* infants
- neourethra construction
 - child, 770-1
 - non-obstetric fistulas, 853
 - obstetric fistulas, 925-6
- nerve(s) (peripheral)
 - conduction studies, 407-9
 - correlation with pathology, 393
 - pudendal nerve, *see* pudendal nerve conduction tests
 - recommendations for research, 418
 - drugs acting on, 103-6, 482-3
 - electrical stimulation (therapeutic), *see* neuromodulation
 - neurophysiological studies, *see* neurophysiological studies
- nerve growth factor (NGF), 96-7
 - in gene therapy, 737
 - inflammation of bladder and, 135
 - obstructed bladders and, 130, 135
 - overactive bladder and, 126, 137
 - sodium channels and, 139
- nerve injury/lesions (incl. denervation of pelvic floor), 702-3, 1100, 1102
 - concentric needle EMG, 401-2
 - in obstructed labour, 910-11
 - pudendal, 408-9
 - biofeedback results, 1011
 - in prediction of surgical outcome, 1016
 - surgery, 1001
 - stress incontinence and, 466-7
 - surgically-associated
 - prostatectomy, 232
 - women, 837
 - see also* reinnervated muscle
- nerve roots, sacral, *see* sacral nerve roots
- nerve-sparing radical prostatectomy, 790
- nerve supply (innervation) to LUT, 24, 46-50, 65, 86-115
 - aging and, 134
 - anal sphincter, 72
 - bladder/bladder wall, 24, 46-50, 100-1
 - detrusor contraction and, 30-3
 - in detrusor overactivity, changes, 129
 - immunolabelling studies, 100-1
 - injury in prostatectomy, 232
 - intrinsic, 30, 46-50
 - denervation (technique), *see* denervation (technique)
 - extrinsic, 24
 - lesions, *see* nerve injury
 - levator ani, 66
 - urethra, 24, 57, 62-3, 101
 - afferent neurones, 24, 98
 - female, 53
 - immunostaining, 101
 - injury in prostatectomy, 232
- Netherlands (Holland and the Dutch)
 - AI prevalence, 988
 - medical professional education, 948
 - physiotherapists, 951
 - sacral root stimulation costs, 978
- neurogenic/neuropathic bladder (in general incl. overactivity)
 - children, 174, 356-7, 526, 539-40, 544-5
 - causes, 174, 356-7, 544
 - enuresis (day and day/night), 174
 - occult/non-neurogenic neurogenic bladder, 539-40
 - urodynamic studies, 356-7
 - mechanisms underlying, 144-5
 - see also* neurogenic/neuropathic LUT dysfunction
- neurogenic/neuropathic detrusor overactivity (hyperreflexia), 133, 207, 331, 701, 729-36
 - areflexia of sphincter with, 702
 - children, 545
 - cystometry, 331
 - definition, 1080
 - electrical neuromodulation, 738-9, 739
 - pharmacotherapy, 728-9, 729-36
 - post-prostatectomy, 558
 - suprapontine lesions and, 207, 699-700
- "neurogenic/neuropathic faecal incontinence", use of term, 987
- neurogenic/neuropathic LUT dysfunction and incontinence, 355-6, 697-754, 865-90, 1069-71, 1100-3
 - classification, 1069-70
 - imaging, 451, 453-4
 - CNS, 456, 467
 - management, 355-6, 697-754, 865-91, 1100-3
 - conservative, 697-754
 - recommended, 1100-3
 - surgery, 865-91
 - outcomes research, 1069-71
 - pattern, 701
 - physical examination, 387, 1100
 - urodynamic studies, 355-6, 1070, 1102, 1112-13
 - see also* neurogenic/neuropathic bladder
- neurogenic/neuropathic sphincter dysfunction or deficiency
 - children, 544-5
 - day or day/night enuresis and, 174
 - drug therapy, 545, 729, 736
- neurography, sensory, 412
 - see also* electroneurography
- neuroimaging, 456-7, 467, 468
- neurokinin (NKs) receptors, 91, 118
 - micturition and, 118
 - NK-2, 95-6
 - antagonists, 106
- neurological disorders/diseases, 699-702
 - bowel in, *see* bowel
 - defaecation and, 997
 - minor, children, 173
 - neuroimaging, 456-7, 467
 - open bladder neck in, 453-4
 - as risk factor for UI, 190, 699-702
 - prostatectomy and, 559
 - urethral sphincter abnormalities, 759
 - see also* central nervous system; nerve supply
- neurological examination, 383-4, 1083
- neurological injury, *see* nerve injury
- neuromodulation, electrical, 737-40
 - anterior sacral nerve roots, *see* sacral nerve roots
 - bladder/detrusor overactivity, 737, 739, 799
- neurones
 - afferent, *see* afferent neurones
 - detrusor contraction control by, 30, 483-6
 - in detrusor overactivity, structural changes, 129
 - dorsal root ganglion, *see* dorsal root ganglion
 - efferent, *see* efferent neurones
 - ischaemic damage, 132-3
 - urethral smooth muscle contraction, 57-60
 - see also* interneurones; motoneurones; raphe neurones
- neuropathic conditions, *see entries under* neurogenic
- neuropathy, autonomic, tests, 416
- neuropeptide Y distribution (and its detection), 100, 101, 102
- neuropharmacology, *see* drug therapy; pharmacology

- neurophysiological studies (incl. electrophysiology), 389-424, 1084
autonomic ganglia, 101
classification of tests, 392
clinical service, 417-18
historical background, 391
methodological considerations, 392-3
new technology, 418
pathological correlations, 393-4
in research, usefulness, 417
sensitivity and specificity, 417
technical standards recommendations, 418-19
tests used, 394-406
see also specific tests
urethral sphincter, *see* urethral sphincter
- neurophysiology, 83-163
clinical, *see* neurophysiological studies
research in, *see* research
- neuroprotection, neurotrophins and, 98
- neurotoxin, *see* botulinum toxin A
- neurotransmitters, afferent neurones, 91
- neurotrophins, 96-8, 147
see also specific types
- neuourology, clinical neurophysiology service, 417-18
- New Zealand
AI prevalence, 988
Continence Association, 964
continence awareness campaign, 943
family doctor services, 955
- newborns, *see* infants
- NGF, *see* nerve growth factor
- nifedipine, 490
- Nigeria, obstetric fistulas, 898, 900, 901
prevention, 957
- night-time, *see entries under* nocturnal
- NIH estimates of costs of UI, 972
- nipple valve construction, 771
- nitrenergic (NOS-containing) nerves
detrusor, 33
urethra, 57
- nitric oxide (NO), 46, 64-5, 94-5
afferent sensitivity and, 95
bladder neck and
female, 50
male, 52
detrusor and, 33, 64
interstitial cells of Cajal and, 102-3
pathophysiology, 64-5
bladder inflammation, 46
bladder obstruction, 144
- nitric oxide synthase, 64-5
inhibitors, micturition effects, 120
nerve terminals containing, *see* nitrenergic nerves
neuronal immunoreactivity for, 100, 101, 102
- NK, *see* neurokinin receptors
- NMDA receptors, 116-17, 118, 122
- NO, *see* nitric oxide
- NOBLE telephone survey, 178
- nociceptin, 96
- nocturia, 631-5
men, drug therapy, 562-3
older people, 631-5
conservative management, 632-5
see also nocturnal diuresis; nocturnal frequency
- nocturnal bladder dysfunction, children, 172
- nocturnal diuresis, older people, 633
see also nocturia; nocturnal frequency
- nocturnal enuresis (bedwetting), 170-3, 518-35, 523-31, 1086
adults
males, 556-7
prevalence, 173
classification, 525-6
primary vs secondary, 169, 525, 556-7
- nocturnal enuresis (bedwetting) – cont'd
definition, 169, 326, 523, 1080
diagnostic work-up, 529
diurnal and, *see* daytime and night-time wetting
evaluation, 518-23
urodynamics, 358, 521-3
long-term outcome, 183
pathophysiology, 526-8
prevalence, 170, 524
adults, 173
risk factors, 170-3
severity, 524
therapy, 528-35
non-responders, 531
pharmacological, *see* drug therapy
- nocturnal frequency, older people, drug therapy, 633-4
see also nocturia; nocturnal diuresis
- nocturnal polyuria
children, 172
men, 562
older people, 631
- nocturnal retention control training, 534
- non-compliance, *see* compliance
- non-neurogenic detrusor or detrusor--sphincter dysfunction (incl. overactivity)
causes, 207-12
children, 537
- non-neurogenic neurogenic bladder, 539-40
- non-steroidal anti-inflammatory drugs (NSAIDs), *see* prostaglandin synthesis inhibitors
- noradrenaline
micturition and, 117
urethral contraction and, 57
- noradrenergic nerves, urethra, 57
female, 53
- noradrenergic pathways, pontine, 122
- norephedrine, stress incontinence, 498
- North America, maternal mortality, 897
- Norwegian Society for Patients with Urologic Diseases, 964
- Nottingham Health Profile, 281
- NPY distribution (and its detection), 100, 101, 102
- nurses, 947-50, 956
education/training, 947-50
specialist, 948-9, 956
- nursing home (and other long-term care institutions for elderly)
AI/FI in, 989-90, 991, 1026
management, 1014, 1031
costs of care, 976-7
minimum data set for residents, 629
staff in
intervention, 655, 657-8
USA, advanced practice gerontological nurses, 957
- nursing services in UK, evaluation of different models, 954
- nutritional factors, *see* dietary factors

O

- OAB-Q (Overactive Bladder Symptom and Health-related QoL), 284
- obesity, female
as risk factor
for pelvic organ prolapse, 246
for UI (in general), 186
stress incontinence surgery outcome and, 838
see also weight reduction
- objective measures in outcome research, 1060
- observational studies of outcome, 1059-60
QoL measures, 292
- observer bias and error, 1053
- obstetrics, *see* childbirth; pregnancy

- obstruction (LUT)
 - bladder, *see* bladder obstruction; bladder outlet obstruction
 - women, pressure-flow studies, 343-4
 - occluding devices
 - extra-urethral, *see* extra-urethral occluding devices
 - urethral
 - costs, 978
 - female, 612-14, 616
 - male (penile urethra), 565
 - older people, 676
 - occupational risk factors, women
 - pelvic organ prolapse, 246
 - UI (in general), 187, 574-5
 - Oceania, maternal mortality, 897
 - odds ratio, 168
 - oestrogen, 466, 500-2, 1064-5, 1094
 - CNS effects, 143-4
 - menopause and, 64-5, 185
 - replacement therapy, *see* hormone replacement therapy
 - risk of UI and levels of, 185
 - status, assessment, 466
 - therapeutic use in incontinence, 104, 500-2
 - pelvic floor muscle training vs, 583
 - stress incontinence, 498, 501
 - urge incontinence, 501-2
 - urethral blood flow and, 63
 - voiding disorders and NO and, 64-5
 - Oklahoma, "Dry Anticipations" project, 943
 - older people/elderly, 133-5, 629-95
 - AI/FI in, 1025-33
 - assessment and diagnosis, 1029-30
 - causes, 1025-6, 1027-9
 - epidemiology, 1025-6
 - pathophysiology, 1025-6
 - treatment, 1030-3
 - bladder, 133-5
 - dysfunction, 629-95
 - physical properties, 134
 - clinical evaluation, 639-46
 - accuracy/specificity/sensitivity, 641
 - algorithms, 639
 - urinalysis, 465, 642, 644-5, 646
 - urodynamic studies, 359-60, 642, 645, 646
 - conservative treatment, 632-5, 647-61, 665-77
 - drugs, *see* drug therapy
 - males, 564
 - nocturia, 632-5
 - epidemiology of UI, 183
 - established incontinence, causes, 638-9
 - frail, *see* frail elderly
 - general recommendations, 684-5
 - identification of UI, 628-9
 - LUT dysfunction, outcome measurement, 646-7
 - nocturia, *see* nocturia
 - nursing homes, *see* nursing home
 - pelvic floor morphology, 70
 - physiologic/pathologic changes, 629-30
 - detrusor overactivity, 210, 629-30
 - prevention of UI, 677-84
 - staff intervention (in long-term care), 655, 657-8
 - surgery, *see* surgery
 - transient incontinence, causes, 635-8
 - Onuf's nucleus, 62, 86, 115-17, 121-2
 - opiate(s) (opioids)
 - micturition and role of, 117, 119, 122-3
 - therapeutic use in FI, 1009
 - opiate (opioid) receptor(s), 117
 - agonists, 96, 99
 - antagonists, 117
 - opiate (opioid) receptor-like receptors, 96
 - orchitis with intermittent catheterisation, 713
 - organisations for continence care, 952-60, 1110
 - orthopaedic trauma in obstructed labour, 910
 - orthotopic neobladder, *see* neobladder
 - outcome, 969-70, 1052, 1057-8, 1058-64
 - definition, 969-70
 - measurement, 969-70, 1058-64, 1111
 - children, *see* children
 - LUT dysfunction in older people, 646-7
 - LUTS, 1058-66
 - in pelvic organ prolapse treatment trials, description of
 - validity/reliability, 256
 - primary, 1052, 1057
 - secondary, 1052, 1057-8, 1111
 - Overactive Bladder Symptom and Health-related QoL (questionnaire), 284
 - overactivity, *see* bladder overactivity; detrusor overactivity
 - overflow AI/FI
 - children (overflow soiling), 1020
 - treatment, 1024
 - older people, 1027, 1027-8
 - overflow soiling, *see* overflow AI
 - overflow UI
 - drug therapy, 499-500
 - older people, 638
 - women, devices, 605-6
 - oxybutinin in bladder/detrusor overactivity, 491-2, 729-30
 - child with daytime enuresis, 543
 - cost-effectiveness analysis, 978
 - extended/controlled release form, 489, 492, 730
 - tolteradine compared with, 732
 - men, post-prostatectomy UI, 561
 - neurogenic UI, 729-30
 - older people, 659-60
 - tolteradine with, 489
 - women
 - bladder training and pelvic floor muscle training vs, 603-4
 - bladder training vs, 601
 - pelvic floor muscle training vs, 583
 - oxyphenacyclimine, 732
 - oxytocin, 123
- P**
- pacemaker activity in urinary tract, 103
 - Pacinian corpuscles, 48
 - pad(s), absorbent
 - for containment, 665-7
 - anal leakage, 1015
 - costs, 668, 973-4
 - men, 564
 - older people, 665-7
 - testing with (pad weighting), 324, 460-4, 1060, 1112
 - data quality, 460-4
 - definition, 460
 - enuresis (child), 519
 - indications/methodology, 460
 - men, preoperative, 788
 - older people, 641, 642, 644, 645, 648
 - recommendations and suggested research, 464, 1084
 - role of investigation, 464
 - see also* bedpads
 - paediatrics, *see* children
 - paracolpium, 67
 - damage, effects, 68
 - paraganglia, 50
 - parallel clinical trials, 1049
 - parasacrococcygeal incision, rectourethral fistula repair, 804
 - parasympathetic nervous system (in LUT), 24, 86, 482-3
 - efferent/preganglionic neurons, *see* preganglionic neurons
 - male bladder neck, 52
 - see also* autonomic nervous system

- parasympathetic nucleus, sacral, 98, 115, 115-17
- paraurethral tissue, *see* connective tissue, paraurethral
- paravaginal repair, 254, 260, 827
 - functional and anatomic outcomes, 376
- parity and stress incontinence surgery outcome, 839
- Parkinson's disease
 - bladder/detrusor overactivity, 141, 699-700
 - constipation and AI, 1028
 - defaecation in, 997
 - EMG, 404
- parturition, *see* childbirth
- pathophysiology
 - of FI, *see* faecal incontinence
 - of nocturnal enuresis, 526-8
 - older people, *see* older people
 - of UI, 203-41
- patients
 - in decision-making, 1085
 - education, intermittent catheterisation, 711, 714-15
 - history, *see* history-taking
 - instructions in leak point pressure measurements, 340
 - position, *see* position
 - selection, for post-prostatectomy UI treatment, 560
 - in trials (of pelvic organ prolapse surgery)
 - clinical care provided, description, 256
 - description of, 256
 - informed consent, 1053
 - population, description, 256
 - selection, 502
- patterned urge-response toileting, 653-4
- payment for drug studies, 1072-3
- pelvic floor, 69-71, 431-50
 - age effects on morphology, 70
 - anatomy, MRI in standardisation of, 444-7
 - connective tissue, 69
 - dysfunction/disorders, 431-50
 - collagen and, 69
 - detrusor overactivity, 210
 - imaging, 431-50, 467
 - treatment costs, 975-6
 - electrical stimulation, *see* electrical stimulation
 - electromyography, *see* electromyography
 - obstetrics and, *see* childbirth; pregnancy
 - PET studies, 125
 - trauma in men, incontinence after, 797, 813
- pelvic floor muscle
 - anatomy, 65-6
 - postpartum, MRI assessment, 445
 - connective tissue in, 69
 - denervation, *see* nerve injury
 - electrical stimulation, *see* electrical stimulation
 - EMG, *see* electromyography
 - exercises, postpartum, 220
 - neurophysiological studies, 419
 - kinesiological EMG, 396
 - strength, 384-5
 - definitions, 384
 - evaluation, 384-5
 - thickness, ultrasound, 439
 - weakness and fatigue, 384
- pelvic floor muscle training (PFMT; pelvic floor exercises), 578-84, 597-8, 615-16
 - definition, 578-9
 - men, 564
 - post-prostatectomy, 560-1
 - older people, 655-6
 - biofeedback-assisted, 648, 649, 650
 - women, 578-84, 597-8, 615-16
- pelvic floor muscle training – cont'd
 - biofeedback-assisted (vs PFNT alone), 586
 - bladder training with (vs other methods), 602-4
 - electrical stimulation with, 591
 - intravaginal resistance devices with (vs PFNT alone), 586
 - other treatments compared with, 582-6, 591, 593, 598, 602-3, 615
 - outcome, 594, 595
 - preventive use, 597-8
 - research recommendations, 617
 - standard vs intensive programs, 582
 - vaginal cones with (vs PFNT alone), 593
- pelvic fracture, open bladder neck, 454
- pelvic organ(s) (and tissues), 66-9
 - co-morbid conditions with prolapse, 247-8, 249
 - supporting structures, 66-9, 222
 - see also specific organs*
- pelvic organ prolapse (POP), 68, 243-65, 835-6, 1065, 1094, 1098-9
 - aetiology, 223-4, 245-6
 - co-morbid conditions, 247-8, 249
 - urinary tract dysfunction and incontinence, 247-8, 835-6
 - epidemiology, 246-9, 258
 - imaging, 249-51, 446, 447-9
 - of anatomy, 446
 - in grading of relaxation, 446-7
 - management, 251-4, 258-61, 835-6, 1098-9
 - costs, 976
 - outcomes measures, 376, 1065
 - recommended, 1094, 1098-9
 - research, 254-6, 257
 - natural history, 248-9
 - nomenclature, 248
 - physical examination, 379, 380, 1083, 1098
 - pudendal terminal latency in, 409
 - unusual forms and mistaken diagnosis, 254
- pelvic organ prolapse -- quantified (POP-Q), 248, 377, 1065
- pelvic pain syndrome, chronic, men, 564
- pelvic skeletal structural variations and pelvic organ prolapse, 246
- pelvic splanchnic nerves, 24
- penile urethra, 55
 - occluding devices, 565
 - see also* bulbourethral sling
- penis
 - biothesiometry, 411
 - clamps, 565, 676
 - condoms/sheaths, *see* condoms
 - dorsal nerve of, *see* dorsal penile nerve
 - mechanical stimulation, pudendal cerebral SEP on, 413
- peranal surgical approaches, *see* transanal approach; transanorectal approach
- perfusion techniques
 - with artificial urinary sphincter, 811
 - urethral pressure measurements, 333-5, 336-7
- periaqueductal grey (PAG) and micturition, 121, 482-3
- perineal approach, rectourethral fistula repair, 804
- perineal pad testing, *see* pads, testing with
- perineal sonography (transperineal), 436
 - bladder neck, 441
 - pelvic floor muscle thickness, 438
- perineal trauma (childbirth), 220-1, 1005-7
- perineometers, 384, 584
- perineourethral fistula, 802
- peripheral models of overactive bladder, 126-35
- peripheral nerves, *see* nerve supply
- peritoneum, anatomical relationships
 - females, 22
 - males, 22
- periurethral bulking agents, *see* bulking agents
- pessaries, 251, 1098
 - as bladder neck support devices, 607, 616
- PET, *see* positron emission tomography
- PGP 9.5 staining, 101

- Pharaonic circumcision, 902
- pharmacists, 951
- pharmacogenomics, 737
- pharmacology
 - central pathways to bladder, 118-20, 122-3, 481-2
 - peripheral pathways to bladder, 103-6, 482-3
 - see also* drug history; drug therapy
- phase I-IV trials, 1049
- phenol injection, transvesical, 877
 - women, 847
- phenoxybenzamine, 500
- phenylephrine, post-prostatectomy UI, 561
- phenylpropanolamine
 - pelvic floor muscle training vs (women), 583
 - post-prostatectomy UI, 561
 - stress incontinence, 498
- Philadelphia Geriatric Center Multilevel Assessment Instrument, 284
- Philippines, Continence Foundation, 964
- phosphodiesterase inhibition, urinary outflow, 60
- physical disability, *see* functional impairment
- physical examination, 373-88, 1082, 1083
 - in artificial urinary sphincter failure, 809
 - child, 383, 387, 761, 1086
 - enuresis, 518
 - FI, 1021
 - female, 379-80, 387, 1083, 1094
 - with BOO, 843
 - pelvic organ prolapse, 379, 380, 1083, 1098
 - in FI, 999, 1108
 - child, 1021
 - older people, 1029
 - future research, 386
 - general aspects, 378-9
 - male, 380-1, 387
 - neurogenic incontinence, 387, 1100
 - older people, 642-3, 645
 - FI, 1029
 - recommendations, 386, 1082, 1083
- physical exercise/activity, stressful, women, 576-7, 615, 1094
 - pelvic organ prolapse and, 246
 - stress incontinence surgery and, 838
 - see also* exercise
- physical therapies
 - in FI, 1010-13
 - men, 564
 - post-prostatectomy, 560-1
 - older people, 647-59
 - women, 578-98, 615-16
 - adverse effects, 594
 - factors affecting outcome, 594-5
 - literature search strategies, 617-18
 - preventive use, 595-8
 - research recommendations, 617
 - in stress incontinence, *see* stress incontinence
 - see also* behavioural therapies
- physical therapists, *see* physiotherapists
- physicians, *see* doctors
- physiology, *see* neurophysiology; pathophysiology
- physiotherapists (physical therapists; PTs), 950-1, 957
 - funding, 957
- physiotherapy, 1071
 - day/night-time enuresis, 541
 - stress incontinence, 854
 - trials/research, 1071, 1113
- pinacidil, 490
- pituitary adenylate cyclase-activating peptide, 01
- placebos
 - drug studies, 502-3, 1073
 - electrical stimulation vs (women), 589-90
 - pelvic floor muscle training vs (women), 581-2
- plain X-rays, *see* X-ray radiography
- polyurethane intravaginal devices, 607, 609-10
- polyuria, nocturnal, *see* nocturnal polyuria
- polyvinyl intravaginal devices, 607, 609-10
- pons (and pontine micturition centre), 116, 120-1, 121
 - imaging studies, 457
 - noradrenergic pathways, 122
 - see also* suprapontine lesions
- POP-Q exam, 248, 377, 1065
- position (patient)
 - in abdominal leak point pressure measurement, 340
 - obstetric fistula repair, 917
 - ultrasound of pelvic floor, 438
 - urethral pressure varying with, women, 335
- positive practice, nocturnal enuresis, 533-4
- positive reinforcement, nocturnal enuresis, 531-2
- positron emission tomography of brain, 457, 458
 - micturition studies, 124-5, 457, 482
- post-anal repair, 1015-16
- posterior urethral valves, 357, 759
- posterior urethrovesical angle, 432
- postmenopausal women, *see* menopausal/postmenopausal women
- Post-Radical Prostatectomy Questionnaire, 279
- Post-Surgical Questionnaire, 279
- postural changes and urine loss, 577-8
- post-void residual urine, *see* residual urine
- potassium ions (and channels)
 - detrusor function and, 27-9, 112
 - openers, uses, 490-1, 737
- pouches (male guards), 666
- power in trials, 1051, 1054
 - pelvic organ prolapse, 255
- practolol, 494
- pragmatic trials, 1055
- preganglionic neurons (PGN), parasympathetic, 98, 99
 - synaptic inputs to, 116-17
 - descending, 116-17
 - segmental, 116
- pregnancy, 217-22
 - as AI risk factor, 990, 991
 - bladder reconstruction and, 778
 - fistulas related to, *see* fistula, women, obstetric
 - history-taking, 1065
 - pelvic floor function and effects of, 217-18
 - subsequent, after 3rd/4th degree obstetric tear, management, 1006-7
 - as UI risk factor, 183
 - see also* childbirth; labour; parity
- preoperative evaluation
 - men, 788-9
 - older women, 661-2
- pressure
 - abdominal, 323-4
 - anorectal, measurement, *see* manometry
 - detrusor, *see* detrusor pressure
 - intravesical, *see* intravesical pressure
 - leak point, *see* leak point pressure
 - measurements (in urodynamic studies), 322-4
 - urethral, *see* urethral pressure
- pressure-flow studies, 343-6
 - abnormalities, interpretation, 343-4
 - in BOO (women), 844
 - future study areas, 346
 - good urodynamic practice, 345
 - indications, 344
 - predictive value, 345-6
 - study results, description, 343
 - technical aspects, 343
- pressure-volume studies, *see* cystometry

- prevalence
 - AI/FI, 988-9
 - older people, 1025-6
 - definition, 168
 - enuresis/wetting
 - day and day/night, 173-4, 536
 - night, *see* nocturnal enuresis
 - pelvic organ prolapse, 247, 258
 - UI (in general), 194
 - men, 188-9
 - reasons for differences in estimates, 191-3
 - research recommendations, 194
 - women, 175
- prevention, 677-84
 - obstetric fistulas, 927-8, 957
 - UI, 677-84, 941-2
 - older people, 677-84
 - physical therapies (women) in, 595-8
 - primary, *see* primary prevention
 - secondary, 677
 - tertiary, 677
- primary prevention, 941-2
 - recommendations, 194, 941-2
- proctography, *see* cystoproctography; defaecography
- proctopexy (rectopexy), 1016
- productivity loss, costs of, 969, 977
- professional education and awareness, 945-51, 1110
 - FI, 988
 - perineal anatomy and obstetric tears, 1009
- progestins, 1065
 - stress incontinence, 501
 - urge incontinence, 501
- prolapse, pelvic organs, *see* pelvic organ prolapse
- prolene tape, *see* tension-free vaginal tape
- promotion of continence care/awareness, 940-5, 1110
- propantheline, 732
 - bladder overactivity, 487-8
 - older people, 660
 - neurogenic UI, 732
 - post-prostatectomy UI, 561
 - women, bladder training and pelvic floor muscle training vs, 603
- propiverine, 493, 730-1
 - children, 543
 - neurogenic UI, 730-1
- propranolol
 - overactive bladder, 494
 - post-prostatectomy UI, 561
- prostaglandin synthesis inhibitors (COX inhibitors; NSAIDs)
 - nocturnal enuresis, 531
 - overactive bladder, 495-6
- prostate cancer, 790-1, 794-5, 813
 - QoL questionnaires, 284-5
 - metastatic disease, 283
 - validated, 305
 - radiotherapy, *see* radiotherapy
 - surgery, *see* prostatectomy, radical
- prostate gland
 - anatomical relationship to bladder, 22
 - benign disease/hyperplasia, *see* benign prostatic hyperplasia
 - cryosurgical ablation, 794-5
 - digital rectal examination, 380
 - fistula involving, *see* prostatocutaneous fistula; prostaticorectal fistula
 - size/volume, treatment affecting, 1064, 1112
- Prostate-Targeted Health Related QoL (questionnaire), 283
- prostatectomy (for BPH and cancer - associated UI), 190-1, 230-4, 557-61, 790-4, 813
 - causes and risk factors for incontinence, 558-60
 - radical prostatectomy, 190-1, 559, 790, 794
 - TURP/TUIP, 792
 - causes of injury, 232
- prostatectomy – cont'd
 - conservative treatment of UI, 560-1
 - estimates of UI, 231-2
 - patient questionnaires, 279
 - imaging, 451
 - non-surgical UI, 558
 - radical (for cancer), 231, 559, 790-1, 794, 813
 - incidence of incontinence, 790
 - radiotherapy and, 559, 794
 - risk factor for incontinence, 190-1, 559, 790, 794
 - surgery for incontinence after, *see subheading below*
 - surgery after, in benign prostate disease, 787, 792-3
 - options, 792-3
 - timing, 792
 - surgery after, in malignant prostate disease (after radical prostatectomy), 787, 790-1, 813
 - options, 790-1
 - timing, 790
 - urodynamic studies for UI after, 233, 353
 - see also* transurethral resection
- prostatic urethra, 55
- prostatocutaneous fistula, 806
- prostaticorectal fistula, 803
- prostheses
 - bladder neck support, 607-10, 616
 - stents (in external urethral sphincter), 873, 886
 - see also entries under* artificial
- protein kinase I, cGMP-dependent, 144
- proteoglycans, bladder, 38-9
 - pathophysiological processes distribution, 39
- provocative stress testing, *see* stress testing
- psychiatric and psychological disorders
 - enuresis/wetting
 - day, 174
 - night, 173
 - overactive bladder, 142-3
 - stress incontinence surgery outcome and, 838
- psychiatry services, childhood FI, 1024
- psychological consequences, children
 - FI, 1021
 - reconstructive surgery, 779
- psychological factors (for incontinence), older people, 643
- psychological management, nocturnal enuresis, 531-5
 - see also specific methods*
- psychological status, stress incontinence, questionnaire, 284
- psychology services, childhood FI, 1024
- psychometric properties, questionnaires, 270-1
- Psychosocial Adjustment to Illness Scale, 285
- Psychosocial Consequence Questionnaire, 284
- psychotherapy, women, bladder training vs, 602-4
- pubic symphysis
 - distance between urethral orifice and, 433
 - trauma in obstructed labour, 910
- public education and awareness, 942-5, 1110
 - in obstetric fistula prevention, 928
- PubMed, 269
- pubococcygeal line, 446, 447
- pubococcygeus muscle, 66
 - EMG, 396, 406
 - tissue analysis in stress incontinence, 466, 467
- puborectalis muscle, 71
 - continence/incontinence and the, 996
 - defaecation and, 997
- pubourethral ligaments, female, 222
- pubovaginal sling
 - neuropathic patients, 880
 - older women, 662
- pudendal nerve, 86
 - injury, *see* nerve injury
 - levator ani innervation, 66
 - reflexes, 99
 - SEPs, 412-13

pudendal nerve conduction tests (incl. terminal motor latency), 407-9, 1001
 FI investigation, 1001
 older people, 1027
 postpartum, 1002-3
 postpartum, 219, 408-9
 research recommendations, 418
 pudendal nerve nucleus (Onuf's nucleus), 62, 86, 115-17, 121-2
 pull-ups, 666
 purinoceptors (and purinergic nerves/innervation), 30, 93-4, 105-6
 bladder wall/detrusor, 30, 106, 107, 483
 P2X family, 93-4, 106
 P2X1, 94, 106, 483
 P2X3, 93-4, 144, 483
 pathophysiological role, 111
 supraspinal pathways in micturition and, 123
 pyelography, intravenous, 428

Q

Q-tip test, 384-5, 385
 QOL9, 286
 quality-adjusted life years (QALY), 968, 980
 quality of life (and its assessment), 279-88, 1062, 1082-3
 bladder expression and, 707
 condom catheters and, 728
 electrical neuromodulation, 738
 electrical stimulation of pelvic floor, 740
 indwelling (long-term) catheters and, 724-5
 questionnaires assessing impact, 267-316, 1062, 1082-3
 AI and, 995-6
 of incontinence, 282-4, 293-5, 306
 individualised measures of impact, 288
 recommendations, 307
 recommended questionnaires, 306
 specific patient groups, 288, 298
 stress incontinence surgery, 837-8
 QUALIVEEN, 288
 questionnaires (bowel symptom), 993-4
 questionnaires (incontinence and QoL), 270-307, 1062
 clinical measures and, relationship, 272-4
 development and testing, 274
 reasons for/importance of, 270
 recommended, 275-89, 306
 in research, 290-8
 research on, 307
 scores/scoring, *see* scoring
 theoretical aspects, 270-4
 QUORUM statement, 1058, 1112

R

race/ethnicity, women
 stress incontinence surgery and, 838
 UI and, 182, 182
 radiography, childbirth-related trauma, 224
 radioisotope scans, upper urinary tract, 430-1
 radiology, *see* imaging
 radiotherapy in prostate cancer, 794
 cystitis due to, surgery, 801
 interstitial, *see* brachytherapy
 prostatectomy and
 radical prostatectomy, 559, 794
 TURP, 794
 radical, QoL questionnaire, 284
 random sampling, 1051
 randomisation, 1051-2, 1055, 1058
 randomised controlled studies, *see* controlled studies
 raphe neurones, serotonergic, 121-2

rat, hypertension model, 137-9
 receptor-effector coupling, detrusor, 33-5
 record, voiding, *see* voiding record
 rectocele, 68, 254, 448
 definition, 254
 imaging, 450
 MRI, 448, 450
 surgery, 248, 254
 rectopexy, 1016
 rectoprosthetic fistula, 803
 rectourethral fistula, 802-6, 813
 rectovaginal fascia attachment, 261
 rectovaginal fistula, obstetric, 908-10
 combined with vesicovaginal fistula, 908, 910
 rectum, 221
 balloons, in biofeedback for FI, 1010
 bladder surgery using, child, 763
 catheters in urodynamic studies, 322
 ambulatory studies, 349
 childbirth and, 221
 compliance, 997
 impaired, 998
 dyschezia, older people, 1027, 1028
 evacuation studies, *see* defaecography
 examination (incl. digital examination), 1082
 child, 383
 male, 380
 older people, 1029, 1030
 women, 1094
 manual evacuation, 1014
 rectourethral fistula approach via anus and, 805
 sensation, *see* sensation
 support, 68-9
 surgery associated with AI risk, 990-1, 992
 ultrasound of/via, 436
 wall contractility, 997
 rectus abdominis flaps, urethral reconstruction, 853
 reflex(es)
 axon, 90-1
 bulbocavernosus, evaluation, 383
 deep tendon, evaluation, 383-4
 in LUT (in general), 86-9
 micturition, *see* micturition reflex
 pathological correlates with studies of, 393
 pudendal nerve, 99
 sacral, *see* anal reflex; bulbocavernosus reflex; sacral reflexes
 storage, *see* storage
 reflex bladder (automatic bladder - reflex voiding), 703
 management guidelines, 704
 reflux, vesicoureteric, *see* vesicoureteric reflux
 regulations affecting costs, 970-1
 regulatory myosin light chain (RLC), 113
 rehabilitation, bladder, 540-1
 reinnervated muscle, single fibre EMG, 404
 relative risk, 168
 relaxation, detrusor, *see* detrusor
 reliability
 outcome measurement in pelvic organ prolapse treatment trials,
 description of, 256
 questionnaires, 271
 ICIQ, 300
 Reliance insert, 612, 613, 613-14, 614
 religion
 obstetric fistulas and, 913-14
 prompted voiding and, 657
 remission
 nocturnal enuresis, 183
 pelvic organ prolapse, 248-9
 UI in women, 180-2
 renal problems/imaging etc., *see* kidney

repair, wound, cellular mechanisms, 216
 reproducibility, questionnaires, 271
 research (incl. future/further research recommendations), 1045-77, 1111-13
 chemical tests, 466
 conservative treatment
 absorbent products, 671-2
 biofeedback-assisted pelvic floor muscle training, 650
 bladder expression, 708
 catheters, 673, 725
 condom sheaths, 675
 drainage bags, 676
 drug therapy, 661, 737
 electrical neuromodulation, 739
 electrical stimulation of bladder, 744
 electrical stimulation of pelvic floor, 741
 men, 566
 neurogenic UI, *see subheading below*
 older people, 638, 650, 657, 661, 671-2, 673, 675, 676, 677
 prompted voiding, 657
 triggered reflex voiding, 705
 women, 617
 cost analyses, 980-1
 endoscopy, 460
 epidemiological studies, 194-5
 general recommendations, 1048-64
 imaging, 450
 bladder wall thickness, 454
 neurogenic incontinence, 451, 457
 open bladder neck and proximal urethra, 454
 pelvic floor (women), 435, 442, 450
 post-prostatectomy, 451
 residual urine evaluation, 453
 upper urinary tract, 431
 methodology, 1045-77
 neurogenic UI
 drug therapy, 737
 triggered reflex bladder, 705
 in neurophysiology, 146
 neurophysiological tests, 418
 neurophysiology in, 417
 older people
 conservative treatment, 638, 650, 657, 661, 671-2, 673, 675, 676, 677
 preventive strategies, 678, 682, 683, 684
 pad testing, 464
 pelvic organ prolapse, 257
 treatment, 254-6, 257
 pharmacology, 146
 therapeutic aspects, 502-3, 661, 737, 1072-3, 1113
 physical examination, 386
 post-prostatectomy UI, 234, 451
 on questionnaires, 307
 questionnaires in, 290-1
 in specific patients groups, 1064-71, 1112-13
 specific types of incontinence research, 1071-4, 1112-13
 surgery (generally), 1113
 surgery in men, 814
 older men, 664
 surgery in women, 854
 older women, 663
 terminology, 1047
 urinalysis, 465
 urodynamic studies, 328
 ambulatory, 351
 cystometry, 333
 leak point pressure, 341
 pressure/flow studies, 346
 recommendations, 360-1
 urethral pressure, 337
 uroflowmetry, 343
 videourodynamics, 349
see also trials

Resident Assessment Instrument, 629
 residential care, *see* nursing home
 residual urine (post-void), elevated, 342
 older people, 629
 women, 1096
 residual urine (post-void), evaluation, 341, 342, 452-3, 1082, 1083
 children, 520
 intermittent catheterisation, 710
 neurogenic incontinence, 1100
 older people, 641-2, 642, 644, 645, 646, 648
 frail/disabled men, 1104
 frail/disabled women, 1106
 women, 1098
 resiniferatoxin, 497, 732, 734-5, 737
 respiratory chain
 smooth muscle, 108
 leak point pressure, 341
 responsiveness to change in questionnaires, 271
 ICIQ, 300-2
 retropubic suspension, 827, 828, 832, 835
 retrovesical angle b measurement, 436, 438, 439
 rhabdosphincter, *see* urethral sphincter
 rhizotomy, sacral, *see* sacral rhizotomy
 ring, intravaginal, 607
 risk
 of procedures, *see* safety
 relative, 168
 risk factors, *see* aetiology
 routine care costs, 969, 973-4
 Royal College of Nursing Continence Forum, 948
 Royal College of Physicians, continence service, 954
 run-in period (crossover trials), 1049

S

sacral agenesis, 356
 FI in, 1020
 imaging
 of open bladder neck and urethra, 453
 of spine, 456
 sacral cord, *see* sacral spinal cord
 sacral nerve roots
 anterior, electrical stimulation/neuromodulation (cauda equina stimulation), 409, 737, 867-8, 877
 costs, 978
 in detrusor overactivity, 799
 in FI, 1018
 in neuropathic patients, 867-8, 877, 885, 1070
 non-therapeutic/experimental studies, 409
 with posterior sacral rhizotomy, 848, 867-8, 877, 885
 posterior/dorsal
 electrical stimulation, 868
 electroneurography, 412
 section, *see* sacral rhizotomy
 sacral nerve stimulation/neuromodulation, *see* sacral nerve roots
 sacral parasympathetic nucleus, 98, 115, 115-17
 sacral reflexes, 414-15, 418, 418-19
 research recommendations, 418
 technical standards recommendations, 418-19
 see also anal reflex; bulbocavernosus reflex
 sacral rhizotomy, dorsal/posterior, 848, 877
 combined with anterior root stimulation, 848, 867-8, 877, 885
 sacral spinal cord, 91, 115-20
 dysfunction, and AI, 1028
 sacral spine
 imaging, 456, 467
 lesions above, 702
 lesions below, 702-3

- sacrocolpopexy, 252, 252-3
 - complications, 253, 260
 - materials, 253
- sacrospinous ligament suspension, 252, 258
- safety aspects (incl. adverse effects and complications)
 - artificial anal sphincter, 1018
 - artificial urinary sphincter, 795, 806-12, 813
 - child, 770
 - bladder expression, 707, 708
 - management of complications, 707
 - bulking agents (periurethral), 841-2
 - colposuspension, 836
 - condom catheters, 726-7
 - prevention of complications, 727-8
 - cystometry, 330
 - desmopressin, 634
 - electrical neuromodulation, 738
 - electrical stimulation of pelvic floor, 740
 - fascial slings, 770
 - indwelling suprapubic catheters, 723
 - indwelling urethral catheters, 719-20, 720-2
 - long-term use, 721-2
 - older people, 673, 719-20
 - short-term use, 720-1
 - intermittent catheterisation, 711-15
 - prevention of complications, 714-15
 - treatment of complications, 715
 - kinesiological EMG, 395
 - physical therapies (women), 594, 604
 - surgery (in general)
 - children, 774-9
 - older people, 662
 - for stress incontinence in women, 836-8
 - triggered reflex voiding, 704, 705
 - see also* drug-induced incontinence
- St Marks stimulator, 408
- Salle procedure, 773
- salt packed in vagina, fistulas caused by, 901
- sampling, 1051
 - methods/strategies, 192, 1051
 - sample size, 1051, 1054-5
- Scandinavia
 - continence organisations, 964
 - specialist nurses, 949
- schistosomiasis (bilharziasis), management of bladder lesions (incl. cystitis)
 - child, 762
 - man, 800
- school and toilet facilities, 1021
- scintigraphy (isotope scans), upper urinary tract, 430-1
- scoring
 - AI, 994-5
 - QoL questionnaires
 - preliminary performance of scores, ICIQ, 303
 - scoring methods/schemes, 271-2, 303
- SEAPI QMM Incontinence Classification System, 284
- self-help costs, 973
- self-catheterisation, intermittent (ISC), 702, 708
 - child, 542
 - material and catheter type, 5-7
 - older people, 673
 - techniques, 710-11
- self-retaining silicone catheters, 605-6
- sensation
 - anorectal
 - discrimination of (in FI therapy), 1010, 1012
 - impaired, 998
 - measurement, 999
 - postpartum, 1003
 - bladder, *see* bladder, sensation
- sensory function evaluation, 383
- "sensory incontinence" (of faeces), use of term, 987
- sensory innervation, 64, 483-4
 - bladder, 48-50, 64, 483
 - detrusor overactivity and disorders of, 210-11
 - see also* afferent neurones
- sensory neurography, 412
- sensory pathways, ascending, 120-2
- sensory system tests, 410-13
- sensory urgency, women, electrical stimulation, 590
- sepsis, intermittent catheterisation, 713
- seromuscular patch, 767-8
- serotonin (5-HT)
 - depression and overactive bladder and, 142-3
 - micturition and, 119, 121-2
- serotonin (5-HT) receptors, 103-5
 - 5-HT-1A antagonists, 105
- serotonergic raphe neurones, 121-2
- services, continence
 - delivery, 952-8, 1110
 - FI, 987
 - see also* support organisations
- severity of FI, assessment, 994, 998
- severity of nocturnal enuresis, 524
- severity of symptoms
 - questionnaires regarding, 10, 273
 - women, 273
 - stress incontinence surgery outcome and, 840
- severity of UI
 - in epidemiological studies, 169, 179-80
 - women, 178-80
 - questionnaire assessing, 278
- sex (gender), urge incontinence and depression and, 143-4
- sex hormones, *see* oestrogen; progestins
- sexual abuse, enuresis and
 - daytime and day/night-time, 174
 - nocturnal, 173
- sexual function/satisfaction, evaluation, 285-7, 376, 1081
 - men, *see* males
 - questionnaires in, 285-7
 - recommended, 306
 - studies using, 296-7
 - validated, 305
 - women, 287, 1066
- sexual intercourse, pain in (dyspareunia), stress incontinence surgery, 837
- SF-36 (Medical Outcomes Study)4, 279-80
- sheaths, penile, 565, 674-5
- shield, *see* liners; male guards
- Shy--Drager syndrome, *see* multiple system atrophy
- Sickness Impact Profile, 281
- sigma-rectum pouch, child, 763
- sigmoid colon
 - in bladder reconstruction/augmentation, child, 765
 - ureter implanted into, 926-7
- sign(s)
 - incontinence as a, 327
 - of voiding difficulty, urodynamic studies in women, 354-5
- significance level, 1054
- SII, *see* Symptom Impact Index
- silastic materials
 - intravaginal devices, 607, 609
 - suburethral slings, 831
- silicone condom catheters, 727, 728
- silicone indwelling catheters, 719
 - complications with, 719-20
- silicone periurethral implants, 833
- Simon Foundation for Continence, 964

- Simple Sexual Function Questionnaire, 287
- Singapore Continence Society, 964
 - CONTInet development, 959
- single blind trial, 1053
- single fibre EMG, 402-4
- single photon emission tomography, CNS, 456-7
- SIP (Sickness Impact Profile), 281
- SIQ (Stress Incontinence Questionnaire), 284
- skeletal muscle disease, EMG, 407
- skeletal structural disorders and pelvic organ prolapse, 246
- skin
 - fistula between
 - and prostate, men, 806
 - and urethra, men, 802, 813
 - fistula-related injury, 911-12
 - infections, economic issues, 976
 - stoma site, 774
- skin care, pads and
 - bedding, 565
 - bodyworn, 667, 668
- skin response, sympathetic, 416
- sleep, children
 - arousal from, *see* arousal; waking
 - nocturnal enuresis and, 172, 527-8
 - urine loss during, quantification, 519
- sleep apnoea, children, 172-3
- sling procedures
 - children, 770
 - men, 812-13
 - older, 664
 - neuropathic patient, 880
 - women, 830-2, 835, 854
 - haemorrhage, 836
 - older, 662
- slow twitch muscle fibres in pelvic floor muscle training, 580
- smoking reduction, 556-7, 575-6, 682
 - men, 556-7
 - women, 575-6, 615
- smooth muscle, 107-15
 - bladder wall/detrusor, 24-35, 107-15
 - cell morphology, 24
 - contraction, *see* contraction
 - in detrusor overactivity, changes, 127-9
 - electromyography, 416
 - intercellular coupling, 114
 - ischaemic damage, 132
 - mechanics, 27
 - metabolism, 108-9
 - role, 35
 - drugs acting on, 103-6
 - energetics, 107-8
 - urethral, 55-61
 - basic properties, 55-7
 - female, 53
 - male, 55
 - role, 61
 - urinary tract (in general), pacemaker signals to, 103
- smooth muscle relaxants, *see* bladder relaxants
- Social Activity Index, sexual aspects, 288
- social consequences, obstetric fistula, 912-14
- social factors, older people, 643
 - see also* cultural aspects
- socioeconomic data as outcome measures, 1063
- sodium ion channels and overactive bladder, 139-41
- soiling
 - definition, 1019
 - functional non-retentive, 1020, 1020-1
 - functional retentive, 1020
 - secondary/voluntary, 1021
- solifenacin, 490
- somatic motor system, *see* motor system
- somatosensory evoked potentials, 412-14
- sonography, *see* ultrasonography
- South Korean continence organisations, 963-4
- spastic cerebral palsy and day or day/night enuresis, 174
- specialists (in continence care), 956-7
 - nurses, 948-9, 956
 - physicians, 947
- SPECT, CNS, 456-7
- sphincter, *see* anal sphincter; urethral sphincter
- sphinctometry, perfusion, with artificial urinary sphincter, 811
- spina bifida
 - bowel training, 1013-14
 - cutaneous stoma site, 774
 - urethral sphincter abnormalities, 759
- spina bifida occulta, imaging, 456
- spinal cord
 - afferent projections to, 91
 - bowel training, 1014
 - lesions (incl. injury/SCI), 700
 - bladder/detrusor overactivity, 136-7, 139, 141, 207, 700, 702
 - botulinum toxin, intravesical injection, 735-6
 - electrical stimulation with, 863
 - imaging of open bladder neck and urethra, 453
 - indwelling catheters and, 721, 724
 - Qol questionnaires on urinary problems, 288
 - reflex bladder with, 703
 - urodynamic studies in children, 356-7
 - sacral, *see* sacral spinal cord
- spinal dysraphism
 - day or day/night enuresis in, 174
 - FI in, 1020
 - imaging, 456
 - urodynamic studies, 356
- spinal micturition reflex in BOO, 135
- spinal SEPs, 412-13
- spine
 - imaging, 456, 467
 - skeletal structural variations and pelvic organ prolapse, 246
- splanchnic nerves
 - pelvic, *see* pelvic splanchnic nerves
 - stimulation in spinal cord injury/disease, 867
- spongy urethra, 55
- staff, nursing home, *see* nursing home
- Stamey grading scale, 1072
- statistics in trials, 1050-8
 - in pelvic organ prolapse, 255-6
- stents, urethral sphincter, 873, 886
- stoma, continent, child, 765, 771-4
 - cutaneous site, 774
- stomach, bladder reconstruction/augmentation using (gastrocystoplasty)
 - child, 765, 766
 - metabolic complications, 776
 - neuropathic patient, 874
- stones, urinary
 - cystoplasty and, 777-8
 - indwelling catheters and, 722
- stools, *see* faeces
- storage dysfunction/failure, 319, 873-8
 - children
 - postoperative, 774-5
 - structural abnormalities causing, 357-8, 757-9
 - as surgical indication, 762
 - neuropathic patients, 873-8
 - in women, devices for, 606-14
- storage phase
 - switch to voiding phase from, 86
 - urodynamics, normal, 320
- storage reflexes, 87, 88, 482
 - neuroanatomy/pathways, 119, 482

- storage symptoms, pharmacotherapy, 562
- straining at defaecation, 997
- stratification (in trials), 1052
- stratified sampling, 1051
- stress incontinence, 222-8, 497-9, 823-41, 1065-6
 - children, 1088
 - cure, definition, 1065-6
 - definition of, 1080
 - denervation and, 466-7
 - drug therapy, 104, 497-9, 501, 737
 - electrical stimulation vs, 592
 - elastase and, 466
 - EMG changes, 404-5
 - endoscopy
 - bladder, 458-9
 - bladder outlet, 458
 - epidemiology, 176-8
 - failed treatment, definition, 1066
 - imaging, 226-8, 454
 - cystourethrography, 433
 - MRI, 226-7, 447
 - ultrasonography, 226-7, 438
 - improvement of, definition, 1066
 - men, conservative management, 564
 - metabolism and, 109-10
 - mixed urge incontinence and, *see* mixed incontinence
 - obstetric risk factors, 184, 217, 218, 223-4
 - older people, 638
 - pathophysiology, 222-8, 466
 - physical therapies in women, 589, 589-90, 590, 591, 854
 - drug therapy vs, 592
 - prolapse surgery resulting in, 835-6
 - questionnaires regarding, 273, 284
 - recommended management in women, 1094, 1096
 - surgery (women), 823-41, 854
 - complications, 836-7
 - historical background, 825
 - literature shortfalls, 825-6
 - non-surgical factors affecting outcome, 838-41, 854
 - procedures reviewed, 826-35
 - surgical factors affecting outcome, 841
 - as symptom or sign, 327
 - urodynamic, 326, 327
 - definition, 1080
 - patient history in prediction of, 328
 - urodynamic studies, 354
 - pressure/flow studies, 344
 - urethral pressure measurements, 226, 335
 - videourodynamic classification, 351
- Stress Incontinence Questionnaire, 284
- stress testing (provocation tests), 385, 1082
 - older people, 643
 - ultrasound in, 438
 - urethral pressure profile, 335
 - women, 1094
- striated muscle
 - abnormal vs normal, concentric needle EMG, 396-402
 - urethral, 61-3
 - female, 53, 54
 - fibre type, 62
 - innervation, 62-3
 - male, 54
 - role, 63
 - see also* urethral sphincter
- strictures, urethral, *see* urethra
- stroke, *see* cerebrovascular accident
- stroma, bladder, *see* bladder
- subjective measures in outcome research, 1059-60
- subsacral lesions, 702-3
- substance P (SP), 48, 50, 91
 - distribution (and its detection), 100, 101, 102
 - micturition and, 118
- subtrigonal injections of denervating agents, *see* bladder, denervating agents
- suburethral sling procedure, 830-2
- superabsorbers, 666
- support organisations, 963-4
 - childhood FI, 1024
 - see also* services
- suprapontine lesions, 1100
 - detrusor overactivity, 207, 699-700
- suprapubic catheters, 723-4
 - indwelling, 702, 723-4
 - compared with urethral catheters, 724
 - complications, 723
 - males, 672-3
 - women, non-obstetric fistulas, 850
- suprapubic manual pressure/tapping, 703, 704
- suprasacral lesions, 702, 1100
- supraspinal lesions, LUT dysfunction, 702
 - see also specific lesions*
- supraspinal pathways in micturition/micturition reflex, 120-1
 - pharmacology, 122-3
- surface EMG, *see* electromyography
- surgery, 755-891, 1073-4
 - AI/FI following, 990-1
 - for AI/FI incontinence, 221, 1015-19, 1108
 - novel techniques, 1017-18
 - with pudendal nerve damage, 1001
 - children, 755-83
 - complications, 774-9
 - consensus statement, 779
 - indications, 762
 - vesicoureteric reflux, 358
 - enterocele, 253
 - external anal sphincter repair, 1005-6
 - men, 785-821
 - evaluation before, 788-9
 - older people, 663-4
 - MRI assessment of anatomy after, 446
 - neuropathic bladder/LUT dysfunction, 865-91
 - obstetric fistula (incl. vesicovaginal fistulas), 910, 916-27
 - complicated questions and surgical questions, 924-7
 - dealing with case backlog, 928-31
 - definition/criteria of success, 915
 - general consensus on basic principles, 916-17
 - older people, 661-4
 - men, 663-4
 - women, 661-3
 - pelvic organ (incl. vaginal) prolapse, 252-4, 835-6, 1098
 - functional and anatomic outcomes evaluated, 376
 - research, 254-6
 - stress incontinence following, 835-6
 - previous history of UI surgery influencing surgical outcome, 839
 - in prostatectomised patients, *see* prostatectomy
 - in prostatectomy, technique modification, 560
 - prostatic, *see* prostatectomy
 - rectocele, 248, 254
 - research, *see* research
 - stress incontinence, *see* stress incontinence
 - trials, 1073-4
 - ureterocele, 357-8
 - for urinary problems (in general), urodynamic studies after, men, 353
 - women, 823-63
 - complications, 836-7
 - confounding variables, 838-41, 854
 - obstetric fistula, *see subheading above*
 - older people, 661-3
 - pelvic floor muscle training vs, 583-4
 - pelvic organ prolapse, *see subheading above*
 - see also specific procedures*

- survey studies
 - enuresis/wetting
 - day and day/night, 173-4
 - night, 170
 - general problems with, 191
- survival analysis in pelvic organ prolapse treatment trials, 255-6
- Sweden
 - nurses, 949
 - Swedish Urotherapists, 964
- sympathetic nervous system (in LUT), 24, 86, 482-3
 - bladder neck
 - female, 50
 - male, 52
 - see also* autonomic nervous system
- sympathetic outflow, lumbar, 99
- sympathetic skin response, 416
- symphysis pubis, *see* pubic symphysis
- symptom(s), 267-316
 - assessment/quantification, 1060, 1082, 1082-3, 1112
 - bowel, in questionnaires, 993-4
 - frail older and disabled people, 1067
 - in pelvic organ prolapse, 1098
 - in QoL studies, *see subheading below*
 - in BOO (women), 842
 - duration of, stress incontinence surgery outcome and, 840
 - impact on QoL, 269
 - incontinence as a, 327
 - lower urinary tract, *see* lower urinary tract symptoms
 - nocturnal enuresis-associated, 525-6
 - in pelvic organ prolapse treatment trials, characterisation, 256
 - in QoL studies, assessment, 270, 275-9
 - recommended questionnaires, 306
 - severity of symptom, 273, 278-9
 - severity, *see* severity of symptoms
 - urodynamic findings and, association, 326-7
 - of voiding difficulty, urodynamic studies in women, 354-5
 - see also* bothersomeness
- Symptom and Psychological Status in Stress Incontinence, 284
- Symptom Impact Index (SII), 283
 - sexual aspects, 288
- Symptom Severity Index, 278
- synaptic inputs to preganglionic neurons, *see* preganglionic neurons
- synthetic materials
 - anterior wall prolapse repair, 254, 260
 - apical prolapse repair (by sacrocolpopexy), 253
 - suburethral slings, 831

T

- taboos, 944-5
- tachykinin(s), 65, 95-6, 106
 - antagonists, 737
 - micturition and, 118
 - see also specific types*
- Taiwan Continence Society, 964
- tampon-type bladder neck support devices, 607, 609
- tamsulosin, 494
- Tanagho procedure, 771, 772
- tape, *see* tension-free vaginal tape
- target difference, 1054, 1055, 1111
- temperature sensation tests, 411-12
 - ice water test, 335, 411-12
- tendinous arch (arcus tendineus) of pelvic fascia, 68
- tendon reflexes, evaluation, 383-4
- tension
 - detrusor, generation, 110-11, 216, 484
 - machinery, 112-15
 - urethral, stress incontinence and, 109-10

- tension-free vaginal tape (TVT), 832-3, 835
 - injury with, 836
- tension receptors, 90
- terminology, *see* definitions and terminology
- terodiline, 543
 - bladder training and pelvic floor muscle training vs, 604
- tetrodotoxin-sensitive Na⁺ channels, 139-41
- thalamic lesions, 125-6
- thermal testing, *see* temperature sensation tests
- "Therevac" micro enemas, 1013
- tissue analysis, 466-7
- tissue engineering, 737
 - women, 849
- tobacco smoking, *see* smoking
- toilet, prompting to, older people, 652
- toilet training, delayed, 1020-1
- toileting (and toileting assistance)
 - children with FI, 1022
 - neurogenic UI, 708
 - older people
 - capacity for/access to, 643, 1029, 1030
 - patterned urge-response toileting, 653-4
- tolterodine, 488, 731-2
 - child, 543
 - costs/cost-effectiveness, 975, 978
- topsheel material
 - bed pads, 670
 - briefs, 669
- Traditional Birth Attendants (Ethiopia), 957
- training of professionals, *see* professional education
- transabdominal approach
 - urethrovaginal fistula (combined with vaginal approach), 853
 - vesicovaginal fistula
 - non-obstetric, 851-2
 - obstetric, 925
- transanal approaches, rectourethral fistula, 804-5
 - endoscopic, 805
- transanorectal approach, rectourethral fistula, 805
- transcutaneous electrical stimulation of anterior sacral roots, *see* sacral nerve
 - roots, anterior, electrical stimulation
- transducers, pressure, 322
- transmembrane transport in bladder, 46
- transperineal approach, rectourethral fistula repair, 804
- transperineal sonography, *see* perineal sonography
- transrectal ultrasound, *see* rectum, ultrasound
- trans-sphincteric approach, rectourethral fistula, 804
- transurethral catheters, *see* urethral catheters
- transurethral incision of bladder neck (TUIBN), women, 845
- transurethral incision of external urinary sphincter (TUIS; sphincterotomy), 872-3, 882
- transurethral resection of prostate (TURP) or incision (TUIP), 558-9
 - radiotherapy and, 794
 - as risk factor for UI, 792, 794
 - prior TURP as risk factor in radical prostatectomy, 559
- transvaginal approach
 - neourethra construction
 - non-obstetric fistulas, 853
 - obstetric fistulas, 925
 - vesicovaginal fistula repair, 851
- transvaginal ultrasound, *see* vaginal ultrasound
- transvesical injection of denervating agents, *see* bladder, denervating agents
- trauma, *see* injury
- treatment
 - algorithms, 1085-109
 - compliance issues, *see* compliance
 - costs of, 969-70, 974-6
 - methods of analysis, 977-80
 - recommendations, 1085-109
 - trials of, *see* trials
 - see also specific modes and specific conditions*

- trials, clinical, 1048-64, 1071-4, 1111-12
 - conduct, 1050-8, 1074
 - conservative therapies, 1071-3
 - pharmacotherapy, 502-3, 1072-3, 1113
 - in women, 578-616
 - day and night-time enuresis, 543-4
 - design, 1048, 1049-50, 1050-1
 - frail older and disabled people, 1067
 - exstrophy-epispadia complex patients, lack of trials, 798
 - inclusion/exclusion criteria, 1048, 1052-3, 1111
 - planning phase/study objectives, 1048-9
 - questionnaires in, 290-2
 - statistics, *see* statistics
 - surgery, 1073-4
 - types, 1049-50
 - see also specific types*
 - see also research*
- tricyclic antidepressants, 104, 732
 - neurogenic UI, 732
 - nocturnal enuresis, 531
 - overactive bladder, 104, 495
- triggered reflex voiding, 702, 703-8
- triple blind trials, 1053
- tropium, 488, 731
 - children, 543
- TURP, *see* transurethral resection of prostate
- tuberculous cystitis, enterocystoplasty, 801
- type II error, 1051
- tyrosine hydroxylase immunostaining, 100, 101, 102

U

- Ucontrol, 943
- UDI, *see* Urogenital Distress Inventory
- U-IIQ, 283, 289
- UK/Britain
 - AI/FI in
 - older people, 1026
 - prevalence, 988-9
 - continence awareness information, 943
 - continence organisations, 964
 - continence services, 953-4
 - family doctors, 955-6
 - cost-effectiveness analysis, 978
 - health surveys with information on UI, 971
 - medical professionals, education/training, 946, 947
 - nurses, 948, 949, 949-50, 956
 - physiotherapists, 951
- ultrafast image acquisition in MRI, *see* dynamic MRI
- ultrasonography, 436-46, 1084
 - children, 761-2
 - residual urine evaluation, 520
 - FI, 1000-1
 - men, preoperative, 788
 - pelvic floor (and its dysfunction), 436-46, 467
 - bladder filling, 438
 - bladder wall thickness, 454
 - examination position, 438
 - measurement, 436-8
 - methodology, 436
 - other imaging modalities compared, 433, 438
 - picture orientation, 436
 - probe-related variations, 438
 - provocation tests, 438
 - recommendations, 442
 - research areas, 442

- ultrasonography – cont'd
 - role of investigation, 439
 - standardisation, 438-9
 - stress incontinence, 226-7, 438
 - three-dimensional, 439, 442
 - urethral diverticula, 455
 - in videourodynamics, 347
- pelvic organ prolapse, 250
- residual urine evaluation, 452
 - children, 520
 - older people, 641, 642, 644, 645, 646, 648
- upper urinary tract, 428-30
 - children, 520
- unblinded trials, 1053
- undergraduate education, 946
- underpads, *see* bedpads
- United Kingdom, *see* UK
- United States, *see* USA
- unstable bladder, *see* bladder instability
- unstable urethra, urethral pressure variations and, 336
- upper motor neurone lesions, evaluation for, 383-4
- upper urinary tract
 - imaging, 428-31, 1083
 - children, 520
 - indications, 428
 - methods, 428-31
 - recommendations and research areas, 431
 - injury in obstructed labour, 906
- urachus, 20
- urapidil, 736
- ureter
 - alternative continence channel construction using, 773
 - bladder augmentation using (ureterocystoplasty)
 - child, 768
 - neuropathic patient, 874
 - women, 849
 - ectopic, *see* ectopic ureter
 - endoscopy, 459
 - imaging, 428
 - injury with obstructed labour, 906
 - in obstetric fistula repair, 918
 - implantation into sigmoid colon in failed repair, 926-7
 - urine reflux, *see* vesicoureteric reflux
- ureterocele
 - ectopic, 759
 - excision, 357-8
- ureterosigmoidostomy, child, 763
- urethra, 52-64, 222-8
 - anatomy, 52-64, 222-3
 - male, *see* males
 - MRI assessment, 445
 - ultrasound examination in stress incontinence, 227-8
 - wall components, 55-64
 - atrophy with artificial urinary sphincter, 806, 811-12
 - bulking agents in/around, *see* bulking agents
 - calibre in women, normal vs abnormal, 843
 - closure, *see* urethral closure
 - connective tissue outside, *see* connective tissue, paraurethral
 - construction/reconstruction, *see* neourethra
 - dilatation (technique), women, 845
 - diverticula, *see* diverticula
 - duplications, 759
 - electrical stimulation, SEPs recorded on, 413-14
 - endoscopy, 457-60
 - erosions with artificial urinary sphincter, 806-9, 812
 - fistula involving, *see* rectourethral fistula; urethrocutaneous fistula
 - funneling, 227
 - hypermobility, 225-6, 351
 - MRI, 445
 - hyperreflexia, and areflexia of detrusor, 702
 - inclination, 432

- urethra -- cont'd
 - incompetence, 336
 - injury/trauma, *see* injury
 - innervation, *see* nerve supply
 - obstruction, women, pressure--flow studies, 343-4
 - see also* urethral strictures
 - occluding devices, *see* occluding devices
 - penile, *see* bulbourethral sling; penile urethra
 - position
 - effects on continence, 223-4, 226
 - studies of, 226
 - prostatectomy-related injury, *see* injury
 - of prosthetic bladder, as weak point, 885
 - proximal
 - open bladder neck and (at rest), imaging, 453-4
 - sacral reflexes obtained on stimulation, 414
 - role/function, 107
 - direct studies, 226
 - electrophysiological studies, 226
 - smooth muscle, *see* smooth muscle
 - stress incontinence and, 109-10, 226
 - imaging studies, 227-8
 - studies of function, 226
 - support
 - structures involved, 68, 222
 - table for recording, 385
 - ultrasound, 436, 440
 - unstable, urethral pressure variations and, 336
 - weakness, concepts of, 224-5
 - see also* entries under transurethral
- urethral catheters (transurethral catheters), 708-23
 - adjunctive therapy, 711
 - fistulas in women (non-obstetric), 850
 - indwelling (incl. long-term), 672-3, 702, 717-23
 - compared with suprapubic catheters, 724
 - effectiveness, 720
 - frequency of change, 719-20
 - safety aspects, *see* safety aspects
 - size, 720
 - technique and materials, 718-20
 - intermittent, *see* intermittent catheterisation
 - neurogenic UI, 708-17
 - older people, 672-3
 - complications, 673, 719-20
 - valves, 674
 - patient education, 711, 714-15
 - safety aspects, *see* safety aspects
 - in urodynamic studies, 322
 - ambulatory studies, 349
 - leak point pressure measurement, 340
- urethral closure pressure, 333, 840-1
 - maximum (MUCP), 335
 - α -agonists increasing, 110
 - urethral instability and variations in, 336
 - stress incontinence and, 836
 - outcome of surgery for, 840-1
- urethral closure pressure mechanism, child, 522
- urethral introducer (for catheters), 709
- urethral meatus, *see* urethral orifice
- urethral orifice/opening/meatus
 - external
 - care with indwelling catheters, 722
 - occluding devices, *see* occluding devices
 - strictures with intermittent catheterisation, 714
 - internal, position
 - cystourethrography, 32, 433
 - ultrasonography, 436
- urethral pressure, 226, 333-7
 - closure pressure, *see* urethral closure pressure
 - maximum (MUP), α -agonists increasing, 110
 - measurements/studies, 320, 324, 333-7
 - abnormalities, interpretation, 336
 - in ambulatory studies, 350
 - future study areas, 337
 - good urodynamic practice, 336-7
 - indications, 320, 336
 - predictive value, 337
 - in stress incontinence, 226, 335
 - study results, description, 335-6
 - technical aspects, 333-5
 - urethral instability and variations in, 336
- urethral pressure profile (UPP), 324
 - resting, 333-5
 - stress, 335
 - women with BOO, 844
- urethral resistance (incl. sphincter resistance)
 - men vs women, 109
 - surgery increasing, 879-81
 - child, 769-70
 - neuropathic patient, 879-81, 886
- urethral sphincter (rhabdosphincter), 61-3, 222-3
 - areflexia, *see* incompetence (*subheading below*)
 - artificial, *see* artificial sphincter
 - bypass by structural anomalies, 759
 - bypass procedures, children, 762
 - contraction, detrusor relaxation and, co-ordination, 30
 - loss, *see* detrusor--sphincter dyssynergia
 - contraction, evaluation, 383, 384
 - control, development, 515-16
 - EMG, 395, 395-6, 397, 398, 402, 406
 - in multiple system atrophy and cauda equina lesions, 404
 - in stress incontinence, 406
 - in urinary retention (women), 406-7
 - external
 - assessment, 384
 - motoneurons, 86, 98-9
 - transurethral incision, 872-3, 882
 - females, anatomy/location, 52, 222-3
 - incompetence/areflexia, 205, 701, 1102
 - detrusor areflexia with, 702
 - detrusor hyperreflexia with, 702
 - incompetence/areflexia in men, 1092
 - post-prostatectomy, 559
 - innervation, 62-3
 - intrinsic sphincter deficiency (ISD), 224-6, 351-2
 - concept of, 224-5, 351-2
 - endoscopy, 458
 - hypermobility and, 225-6, 351
 - predictive value, 351-2
 - recommended management in women, 1094
 - surgery, 879-80
 - vaginal movement and, interaction causing UI, 229
 - male, anatomy, 55, 230
 - muscle augmentation, 879-80
 - neurophysiological studies, 226
 - EMG, *see subheading above*
 - in rectourethral fistula approach, 804
 - resistance, *see* urethral resistance
 - stents, 873, 886
 - tone, evaluation, 383
 - ultrasound, 436, 440, 441
 - see also* striated muscle, urethral
- urethral sphincter dysfunction
 - neuropathic, *see* neurogenic/neuropathic sphincter dysfunction
 - non-neurogenic, *see* non-neurogenic detrusor or detrusor--sphincter dysfunction
 - paediatric/congenital causes, 759, 760
 - surgery, 762

- urethral strictures
 - with intermittent catheterisation, 713, 714
 - prevention, 715
 - prostatectomy patients, 793
 - treatment, 715
 - urodynamics in children, 358
- urethral valves, posterior, 357, 759
- urethritis with intermittent catheterisation, 713, 714
- urethrocutaneous fistula, men, 802, 813
- urethrography, diverticula, 455
 - see also* cystourethrography
- urethrolisis, BOO in women, 845
- urethropelvic angle, 432
- urethroperineal fistula, 802
- urethroscopy, *see* endoscopy
- urethrovaginal fistula, non-obstetric, 853
- urethrovesical angle, posterior, 432
- urethrovesical junction, *see* bladder neck
- urge FI, 1108
- Urge-IIQ, 283, 289
- Urge Incontinence QoL questionnaire, sexual aspects, 288
- urge-response toileting, patterned, 653-4
- urge syndrome, *see* urgency
- urge UI
 - aetiology/pathogenesis, 109, 131
 - children, 537-8, 1088
 - definition, 327, 1080
 - depression and, *see* depression
 - gender and, 143-4
 - see also* men; women (*subheadings below*)
 - men, 1090
 - conservative treatment, 564
 - recommended management, 1090
 - surgery for refractory incontinence, 799, 813
 - mixed stress incontinence and, *see* mixed incontinence
 - older people, 638
 - drug therapy, 659
 - QoL questionnaires, 283, 288, 289
 - urodynamic studies, 354
 - pressure--flow studies, 344
 - women, 354
 - women
 - definition of outcome, 1066
 - depression and, 143-4
 - drug therapy, 501-2
 - electrical stimulation, 589, 590
 - epidemiology, 177
 - recommended management, 1096
 - urodynamic studies, 354
- Urge-Urinary Distress Inventory, 276
- urgency (incl. urge syndrome; urgency-frequency syndrome), 130-1
 - children, 537-8
 - therapy, 538
 - diagnosis, 538
 - hormone therapy, 501
 - men, 1090
 - NO and, 64
 - theories (of pathogenesis), 130-1
 - women, 1066, 1092
 - electrical stimulation, 589, 589-90, 590
 - outcomes, 1066
 - see also* bladder overactivity
- urinals, handheld, 676-7
- urinalysis, 465, 1082
 - children, 518
 - older people/elderly, 465, 642, 644-5, 646
- urinary bladder, *see* bladder
- urinary diary, *see* frequency/volume diary
- urinary diversion
 - conduit (non-continent), *see* conduit urinary diversion
 - continent, *see* continent urinary diversion
 - for unsuccessful exstrophy/epispadia surgery, 798
 - for unsuccessful obstetric fistula repair, 926-7
 - women, 849
- urinary sphincter
 - artificial, *see* artificial sphincter
 - natural, *see* urethral sphincter
- urinary tract
 - lower, *see* lower urinary tract
 - upper, *see* upper urinary tract
- urinary tract infections
 - artificial urinary sphincter-related, 806-9, 812
 - children
 - bladder reconstruction/augmentation and, 777-8
 - day or day/night enuresis, 174, 536
 - urodynamic studies, 358
 - indwelling catheter-related, 718-19
 - intermittent catheterisation-related, 711-13
 - prevention, 714-15
 - treatment, 715
 - older people, 636
 - stress incontinence surgery-related, 837
 - women, 1094
 - persistent, 1096
 - see also* bacteriology; bacteriuria; cross-infection; cystitis; sepsis; urethritis
- urination, *see* micturition; voiding
- urine
 - absorbent disposable products and effects of, 667
 - analysis, *see* urinalysis
 - collection devices (external), *see* collection devices
 - composition, effects on volume voided, 46
 - containment devices, 564-5
 - flow, *see* urine flow
 - leakage, *see* leakage
 - loss (in enuresis), quantification, 519
 - residual, *see* residual urine
 - storage, *see* storage
 - vaginal entrapment (girls), 540
 - volumes voided, *see* voided volume
- urine flow (and flow rate)
 - bladder pressure and, relationship, *see* pressure--flow studies
 - child, normal rate, 517
 - measurement, *see* uroflowmetry
 - phosphodiesterase inhibition affecting, 60
- urine retention
 - chronic, leakage with, *see* overflow UI
 - night-time control training, 534
 - women
 - with BOO, 843
 - concentric needle EMG, 406-7
 - electrical stimulation, 589
- urodynamic stress incontinence, *see* stress incontinence
- urodynamic studies, 317-72, 1061, 1074, 1083, 1084, 1112
 - ambulatory, *see* ambulatory urodynamics
 - artificial urinary sphincter failure, 809
 - blood flow recording and, 42
 - children, 356-9, 762, 1086
 - enuresis, 358, 521-3
 - technical aspects, 359
 - clinical applications, 352-60
 - data, variability, 325
 - equipment/instruments, 322, 324-5
 - general aspects, 321-8
 - imaging combined with, *see* videourodynamics
 - indications, 319-21
 - investigator's role, 321-2
 - men, 350-3, 1092
 - exstrophy-epispadia complex patients, 798
 - preoperative, 788
 - pressure--flow studies, predictive value, 346

methods used, 328-52
see also specific methods
 neuropathic LUT dysfunction, 355-6, 1070, 1102, 1112-13
 older people, 359-60, 642, 645, 646
 pelvic organ prolapse, 251
 post-prostatectomy UI, 233, 353
 recommendations, 1061, 1083, 1113
 for clinical practice, 360-1, 1061
 for future research, 360-1
 results, interpretation, 325-7
 study conditions, description, 325
 women, *see females*
 uroflowmetry, 320, 341-6, 1083
 abnormalities, interpretation, 342
 children, 520
 ultrasound and, 520
 future study areas, 343
 good urodynamic practice, 342
 indications, 320, 342
 predictive value, 342
 study results, description, 341-2
 technical aspects, 341
 women with BOO, 843-4
 urogenital diaphragm
 female, 222-3
 male, 230
 Urogenital Distress Inventory (UDI), 276
 short form version, 276, 283
 urogenital fistula, *see fistula*
 urogenital sinus malformation, 759
 urography, intravenous, 428
 UroLume, 873
 uroneurology, clinical neurophysiology service, 417-18
 uroplakins, 43
 urothelium, 43-6, 91-3
 basal layer, 43, 46
 in female paediatric surgery, autologous grafts, 849
 function, 91-3
 intermediate layer, 43, 46
 NO and the, 95
 in paediatric surgery, 774-5
 autologous grafts, 768-9
 colocystoplasty lined with urothelium (=seromuscular patch),
 767-8
 superficial layer, 43-6
 urotherapy (bladder rehabilitation), 540-1
 USA (America)
 AI/FI in
 older people, 1026
 prevalence, 989
 continence awareness promotion, 940, 942-3
 continence organisations, 964
 continence services
 funding, 957-8
 needs of service users, 953
 protocols and guidelines, 958
 cost-benefit analysis, 979-80
 cost-effectiveness analysis, 977
 family doctors, education, 946-7
 FDA on anti-incontinence device studies, 1071-2
 health surveys with information on UI, 971
 hospital accounting systems, 971
 NIH estimates of costs of UI, 972
 nurses and their education, 950, 956-7
 nursing home costs, 977
 routine care costs, 974
 women, race and UI occurrence, 182
 uterine damage in obstructed labour, 907-8
 uterine prolapse, MRI, 448-9
 uterosacral ligaments, 67
 damage, 223
 uterosigmoidostomy, obstetric fistulas, 926-7
 U-UDI, 276

VACTERL association, 357
 vacuum delivery, effects, 1008
 vagina
 apical, *see vaginal wall, apical*
 bladder neck support devices in, 607-10, 616
 caustic substances put in, fistulas caused by, 901
 damage/injury in childbirth, 223
 in obstructed labour, 906-7
 defects, 68
 delivery via, *see childbirth*
 fistulas involving, *see rectourethral fistula; rectovaginal fistula;*
 urethrovaginal fistula; vesicovaginal fistula
 movement, in UI causation, 229
 in obstetric fistula repair, 918
 physical examination, 379, 1082, 1094
 resistance devices in, 584-6
 salt packed in, fistulas caused by, 901
 supporting structures, 67-9, 222-3
 urine entrapment (girls), 540
 see also entries under colpo-
 vaginal approach, *see transvaginal approach*
 vaginal biofeedback, pelvic floor muscle training vs (women), 584-6
 vaginal catheters, ambulatory urodynamics, 349
 vaginal cones, weighted, 585, 592-4
 pelvic floor muscle training vs, 583
 preventive use, 598
 vaginal prolapse, 252-4, 258-61
 childbirth and, 223-4
 imaging studies, 249
 treatment, 252-4, 258-61, 845
 functional and anatomic outcomes evaluated, 376
 vaginal tape, tension-free, *see tension-free vaginal tape*
 vaginal ultrasound (transvaginal), 436
 bladder wall thickness, 454
 see also introital sonography
 vaginal wall, anterior, 68
 defects, *see cystocele*
 prolapse/descent
 diagnostic imaging, 249
 physical examination, 380
 treatment, 253-4, 260
 vaginal wall, apical, descent
 physical examination, 380
 suspension, 252-3, 258
 vaginal wall, posterior, 68-9
 defects, 68
 prolapse/descent
 diagnostic imaging, 249
 physical examination, 380
 treatment, 253, 254, 261
 vaginal wall sling/island, older women, 662
 vaginitis, atrophic, 636
 validity
 questionnaires, 270-1, 305
 ICIQ, 299-300
 randomised trials, 291
 validated questionnaires, 305
 trials, 1051
 pelvic organ prolapse, 255-6
 Valsalva manoeuvre
 bladder expression using, 705-8
 leak point pressure in, 225, 338
 definition, 338
 preoperative, men, 788-9
 ultrasound during, 438

- valves
 - catheter, 673-4
 - implantable intraurethral, 880-1
 - vanilloids, 732-5
 - receptors for (VR1), 91-3, 96
 - therapeutic use, 496-7, 729, 732-5, 737
 - vasculature, *see* blood vessels
 - vasoactive intestinal polypeptide-staining neurones, 100, 101, 102
 - vasopressin (arginine vasopressin; ADH)
 - aging and release of, 629-30
 - analogues, *see* desmopressin
 - nocturnal release, lack, 526-7
 - older people, 631
 - VATERL association, 357
 - venous drainage, bladder, 39
 - ventouse (vacuum) delivery, effects, 1008
 - verapamil, 490
 - vesicoanal reflex, 414
 - vesicoureteric reflux
 - children, 358, 536-7
 - indwelling catheters, 721-2
 - vesicourethral reflex, 414
 - vesicovaginal entrapment (of urine), 540
 - vesicovaginal fistulas
 - non-obstetric, 849-50
 - aetiology, 849-50
 - obstetric (in developing world), 184, 893-935
 - causes, 902-14
 - children, 759
 - combined with rectovaginal fistula, 908, 910
 - endoscopy, 459
 - epidemiology, 898-902
 - surgery, *see* surgery
 - see also* fistula, women, obstetric
 - vibration, sensory testing, 411
 - videourodynamics (urodynamics + imaging), 320, 347-9, 432, 1084
 - abnormalities, interpretation, 348-9
 - children (enuresis), 522-3
 - future study areas, 349
 - good urodynamic practice, 349
 - indications, 320, 349
 - predictive value, 349
 - stress incontinence classification, 351
 - study results, description, 348
 - technical aspects, 347-8
 - urethral diverticula, 845-6
 - VIP-staining neurones, 100, 101, 102
 - visceral injury in stress incontinence surgery, 836
 - visceral pelvic fascia, *see* fascia
 - visualisation in nocturnal enuresis, 532
 - vitamin B₁₂ deficiency and intestinal reservoirs, 776
 - vitamin C and connective tissue strength, 212-13
 - Viva insert, 612, 613
 - Voided Patterns (Denmark), 279
 - voided volume (volumes voided), urine composition affecting, 46
 - voiding
 - children
 - desire, 535
 - dysfunctional, 539, 1088
 - normalised (as treatment method), 533
 - pattern, 517
 - disorders/dysfunction/difficulty, 319
 - children, 539, 1088
 - electrical stimulation (women), 589
 - intermittent catheterisation in, 711
 - NO and, menopausal women, 64-5
 - recommended management in women, 1096
 - stress incontinence-related, 837
 - urodynamic classification, 325
 - urodynamic studies with symptoms or signs of, women, 354-5
 - pelvic organ prolapse and effects on, 247
 - pressure--flow studies, *see* pressure--flow studies
 - prompted
 - men, 564
 - older people, 651-7, 658
 - prosthetic bladder, 884-5
 - reflex, *see* reflex bladder
 - scheduled/timed, men, 563
 - triggered reflex, 702, 703-8
 - see also* micturition
 - voiding colpocystourethrography, 435
 - voiding cystourethrography, *see* cystourethrography
 - voiding diary, *see* frequency/volume diary
 - voiding phase
 - switch from storage phase to, 86
 - urodynamic findings, normal, 320
 - voiding record/documentation, older people, 641, 642
 - see also* frequency/volume diary; pads, testing with; wet checks
 - voiding reflex, *see* micturition reflex
 - volume
 - bladder, *see* bladder, volume
 - voided, urine composition affecting, 46
 - see also* frequency/volume chart; frequency/volume diary
 - volume receptors, 90
- W**
- waking
 - scheduled, 534
 - to void (nocturia), men, drug therapy, 562-3
 - see also* arousal
 - washout period (crossover trials), 1049
 - web, education resources, 951-2
 - weight reduction
 - men, 555
 - women, 573-4, 614
 - see also* obesity
 - weighted scores in questionnaires, 272
 - wet checks, older people, 641, 642, 643-4, 645, 648
 - wetting, *see* enuresis
 - Wexner score, 994
 - modified version, 995
 - Wisconsin, AI prevalence, 989
 - women, *see* females
 - work, *see* occupational risk factors
 - World Wide Web, education resources, 951-2
 - worldwide issues, *see entries under* international
 - wound infection in stress incontinence surgery, 837
 - wound repair, cellular mechanisms, 216
- X**
- X-ray radiography (plain films)
 - artificial urinary sphincter failure, 809
 - childbirth-related trauma, 224
 - lumbosacral spine, 456
- Y**
- YIPS (York Incontinence Perceptions Scale; York Questionnaire), 284, 978
 - YM-905, 490
 - York Incontinence Perceptions Scale (York Questionnaire), 284, 978
 - York--Mason approach, 804
 - Young--Dees--Leadbetter procedure, 771, 772